Page last updated: 2024-11-06

dobutamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dobutamine is a synthetic catecholamine that acts as a β1-adrenergic receptor agonist. It is used clinically as an inotropic agent to increase cardiac contractility and improve cardiac output in patients with heart failure. Dobutamine's synthesis involves attaching a butyl group to the amine group of dopamine, creating a more potent and selective β1-agonist. It has a relatively short half-life, making it suitable for intravenous administration. Dobutamine's effects include increasing heart rate, contractility, and cardiac output, leading to improved tissue perfusion and reduced symptoms in heart failure patients. It is commonly studied to understand its efficacy and safety in various clinical settings, including acute heart failure, cardiogenic shock, and perioperative management. Research on dobutamine aims to optimize its dosage, investigate potential adverse effects, and compare its effectiveness with other inotropic agents. '

Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID36811
CHEMBL ID926
CHEBI ID4670
SCHEMBL ID21237
MeSH IDM0006696

Synonyms (101)

Synonym
BRD-A78322124-003-03-3
gtpl535
4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol
dobutamine (usan/inn)
D03879
BSPBIO_000443
PRESTWICK2_000352
PRESTWICK3_000352
LOPAC0_000365
34368-04-2
C06967
dobutamine
rac-dobutamine
DB00841
racemic-dobutamine
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
dl-dobutamine
3,4-dihydroxy-n-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
(+/-)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
NCGC00024629-03
(+-)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
ly 81929
dobutamina [inn-spanish]
dobutaminum [inn-latin]
1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+-)-
SPBIO_002364
PRESTWICK0_000352
PRESTWICK1_000352
BPBIO1_000489
NCGC00024629-02
HMS2089K05
NCGC00015321-05
CHEBI:4670 ,
dobutaminum
dobutamina
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
compound 81929
CHEMBL926 ,
compound-81929
racemic dobutamine
4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
L001157
NCGC00015321-04
cid_36811
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol(dobutamine)
bdbm50325274
tox21_110126
cas-34368-04-2
dtxcid702958
dtxsid3022958 ,
CCG-204460
SR-01000075265-9
NCGC00015321-06
NCGC00015321-08
NCGC00015321-07
NCGC00015321-03
NCGC00015321-09
unii-3s12j47372
dobutamine [usan:usp:inn:ban]
3s12j47372 ,
dobutamine [usan]
FT-0625556
STL373008
dobutamine [vandf]
1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-
dobutamine [usp impurity]
1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+/-)-
67230-43-7
dobutamine [mi]
4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-1,2-benzenediol
dobutamine [who-dd]
(+/-)-dobutamine
dobutamine [inn]
BBL033719
SCHEMBL21237
NCGC00015321-11
tox21_110126_1
1,2-benzenediol, 4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-, (.+/-.)-
4-(2-([3-(4-hydroxyphenyl)-1-methylpropyl]amino)ethyl)-1,2-benzenediol #
(.+/-.)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]pyrocatechol
AKOS025248013
dobutaminehydrochloride
4-[2-[[3-(4-hydroxyphenyl)-1-methyl-propyl]amino]ethyl]benzene-1,2-diol
Q422782
VS-12236
SDCCGSBI-0050353.P002
NCGC00015321-18
AMY40802
4-(2-(4-(4-hydroxyphenyl)butan-2-ylamino)ethyl)benzene-1,2-diol
EN300-18539446
HY-15746A
CS-0013581
4-(2-((4-(4-hydroxyphenyl)butan-2-yl)amino)ethyl)benzene-1,2-diol
c01ca07
3,4-dihydroxy-n-(3-(4-hydroxyphenyl)-1-methylpropyl)-beta-phenylethylamine
4-(2-(3-(4-hydroxy-phenyl)-1-methyl-propylamino)-ethyl)-benzene-1,2-diol
dobutamine (usan:usp:inn:ban)
dobutamina (inn-spanish)
dobutaminum (inn-latin)
dobutamine (usp impurity)
dobutamin

Research Excerpts

Overview

Dobutamine is a rare and unrecognized cause of eosinophilic myocarditis (EM) With dobutamine stress there is a decrease in EDVi. Dobutamine CMR could be used as a specific endpoint in a small clinical trial.

ExcerptReferenceRelevance
"Dobutamine is an inotropic agent given to patients with low cardiac output or undergoing cardiac surgery in intensive care units. "( Long-term stability of 10 mg/mL dobutamine injectable solutions in 5% dextrose and normal saline solution stored in polypropylene syringes and cyclic-oleofin-copolymer vials.
Barthélémy, C; Carta, N; Décaudin, B; Genay, S; Gilliot, S; Henry, H; Odou, P, 2023
)
2.64
"Dobutamine is a β-adrenergic agonist with an affinity higher for receptor expressed in the heart (β1) than for receptors expressed in the arteries (β2). "( Cardiac stress test induced by dobutamine and monitored by cardiac catheterization in mice.
Calligaris, SD; Conget, P; Ricca, M, 2013
)
2.12
"Dobutamine is an inotrope with vasodilator properties that improve hepatosplanchnic perfusion."( Effect of intraoperative dobutamine on splanchnic tissue perfusion and outcome after Whipple surgery.
Elkharboutly, W; Elmorshedi, M; Hasaneen, NA; Reyad, AR; Wahba, A, 2013
)
1.41
"Dobutamine is a rare and unrecognized cause of eosinophilic myocarditis (EM). "( Dobutamine induced eosinophilic myocarditis and right heart failure requiring emergent biventricular assist device implantation.
Katlaps, GJ; Lewis, NP; Mankad, AK; Quader, MA; Raje, VP; Shah, KB,
)
3.02
"With dobutamine stress there is a decrease in EDVi."( Ventricular function and cardiac reserve in contemporary Fontan patients.
Bossers, SS; de Rijke, Y; Helbing, WA; Kapusta, L; Kroft, LJ; Kuipers, IM; Moelker, A; Romeih, S; Ten Harkel, AD; van Iperen, G, 2015
)
0.87
"Dobutamine is a cardiotonic agent, developed as a racemate more than 30 years ago. "( "The β1-selective adrenoceptor agonist dobutamine": a fallacy being perpetuated.
Waldeck, B, 2011
)
2.08
"Dobutamine is a sympathomimetic drug, which can be used in patients with dilated cardiomyopathy (DCM). "( [Is intermittent dobutamine treatment beneficial in patients with dilated cardiomyopathy?].
Abaci, A; Başar, E; Cetin, S; Ergin, A; Eryol, NK; Güven, M; Topsakal, R, 2002
)
2.1
"Dobutamine (201)Tl SPECT is a useful method for detecting patients with significant CAV and assessing prognosis. "( Diagnostic and prognostic value of dobutamine thallium-201 single-photon emission computed tomography after heart transplantation.
Chou, NK; Ho, YL; Huang, PJ; Lee, CM; Wang, SS; Wu, YW; Yen, RF, 2005
)
2.05
"Dobutamine CMR is a highly reproducible technique with very good inter-observer variability and could be used as a specific endpoint in a relatively small clinical trial."( Reproducibility and inter-observer variability of dobutamine stress CMR in patients with severe coronary disease: implications for clinical research.
Arai, AE; Cannon, RO; Hill, J; Ingkanisorn, WP; Paterson, DI; Rhoads, KL; Syed, MA, 2005
)
2.02
"Dobutamine is a synthetic catecholamine frequently used in patients with septic myocardial dysfunction."( Dobutamine does not influence inflammatory pathways during human endotoxemia.
de Kruif, MD; Giebelen, IA; Heesen, M; Lemaire, LC; Levi, M; van der Poll, T, 2006
)
2.5
"Dobutamine stress MCPI is a useful technique for the evaluation of coronary artery bypass graft disease."( Noninvasive diagnosis of coronary artery bypass graft disease by dobutamine stress real-time myocardial contrast perfusion imaging.
Elhendy, A; O'Leary, EL; Porter, TR; Tsutsui, JM; Xie, F, 2006
)
2.01
"Dobutamine is a synthetic catecholamine developed as a relatively selective positive inotropic drug for short-term parenteral administration. "( Drugs five years later. Dobutamine.
Leier, CV; Unverferth, DV, 1983
)
2.02
"Dobutamine is a directly acting inotropic agent which increases myocardial contractility without significantly changing blood pressure."( Vascular and uterine responses to dobutamine and dopamine in the gravid ewe.
Fishburne, JI; Greiss, FC; James, FM; Meis, PJ; Rhyne, AL; Swain, MF; Urban, RB; Wheeler, AS, 1980
)
1.26
"Dobutamine is a new inotropic agent that may induce prolonged clinical improvement in patients with congestive cardiomyopathy. "( Improvement of human myocardial mitochondria after dobutamine: a quantitative ultrastructural study.
Baba, N; Croskery, R; Dick, MR; Kolibash, AJ; Leier, CV; Magorien, RD; Meacham, JA; Svirbely, JR; Unverferth, DV, 1980
)
1.96
"Dobutamine is an effective pharmacologic stress agent because of its beta-adrenergic receptor agonist properties. "( Effect of beta-adrenergic receptor blockade on the physiologic response to dobutamine stress echocardiography.
Guerrero, JL; Levangie, MW; Newell, JB; Picard, MH; Weissman, NJ; Weyman, AE, 1995
)
1.96
"With dobutamine, the stimulus is a beta-receptor mediated effect on myocardial cell, which is later matched by an increase in flow."( Detection of viable myocardium by dobutamine and dipyridamole stress echocardiography.
Bento de Sousa, MJ; de Moura Duarte, LF; Picano, E; Pingitore, A; Sicari, R, 1994
)
1.02
"Dobutamine MRI is an accurate method for detection and localization of myocardial ischemia and may emerge as a new noninvasive approach for evaluation of patients with known or suspected coronary artery disease."( Magnetic resonance imaging during dobutamine stress for detection and localization of coronary artery disease. Quantitative wall motion analysis using a modification of the centerline method.
Bruschke, AV; de Roos, A; Matheijssen, NA; Reiber, JH; Spanjersberg, SJ; van der Wall, EE; van Dijkman, PR; van Rugge, FP; Zwinderman, AH, 1994
)
1.29
"Dobutamine MIBI SPET is a well-tolerated, non-exercise-dependent test for detection and localisation of haemodynamically significant coronary artery stenoses.(ABSTRACT TRUNCATED AT 250 WORDS)"( Dobutamine 99mTc-MIBI single-photon emission tomography: non-exercise-dependent detection of haemodynamically significant coronary artery stenoses.
Baer, FM; Schicha, H; Schneider, CA; Sechtem, U; Theissen, P; Voth, E, 1994
)
2.45
"Dobutamine is a predominant beta-1 agonist that increases heart rate, myocardial contractility and systolic blood pressure."( Dobutamine myocardial perfusion imaging.
Verani, MS, 1994
)
2.45
"Dobutamine MRI is an accurate nonexercise-dependent method for the assessment of myocardial ischemia in patients with coronary artery disease."( Dobutamine stress magnetic resonance imaging for detection of coronary artery disease.
Bruschke, AV; de Roos, A; van der Wall, EE; van Rugge, FP, 1993
)
3.17
"Dobutamine is a sympathomimetic drug (beta 1 agonist) that increases myocardial contractility and at high doses also systolic arterial blood pressure and heart rate."( Cardiac study by dobutamine stress echocardiography in thalassemic patients.
Agostini, A; Angelucci, E; Cesaroni, P; Lucarelli, G; Mariotti, E; Sgarbi, E, 1993
)
1.35
"Dobutamine is a useful stress agent by virtue of its safety, operator control and its effects which resemble physical exercise."( Quantitation of global and regional left ventricular function by cine magnetic resonance imaging during dobutamine stress in normal human subjects.
Bruschke, AV; de Roos, A; Holman, ER; van der Laarse, A; van der Wall, EE; van Rugge, FP, 1993
)
1.22
"Dobutamine is an effective pharmacologic stress used in conjunction with echocardiography because of its beta-agonist properties. "( Effect of beta-blockade on dobutamine stress echocardiography.
Guerrero, JL; Levangie, MW; Picard, MH; Weissman, NJ; Weyman, AE, 1996
)
2.03
"Dobutamine proved to be a very sensitive method to detect clinical and subclinical cardiac dysfunction in patients post anthracycline chemotherapy and questions the concept of a safe dose."( Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors.
Benoit, Y; De Wolf, D; Matthijs, D; Maurus, R; Otten, J; Suys, B; Verhaaren, H, 1996
)
2.46
"Dobutamine is a positive inotropic and chronotropic agent and is being widely used as a pharmacologic stress agent in patients unable to achieve maximal dynamic exercise test. "( Dobutamine thallium-201 myocardial SPECT in patients with left bundle branch block and normal coronary arteries.
Aras, T; Bekdik, C; Caner, B; Elahi, N; Kabakci, G; Kes, S; Rezaghi, C; Tokgozoglu, L; Ugur, O; Uysal, U, 1997
)
3.18
"Dobutamine is a synthetic catecholamine with predominant beta-stimulation. "( Dobutamine stress echocardiography.
Gödke, J; Gülker, H; Ketteler, T; Krahwinkel, W; Krakau, I; Ulbricht, LJ; Wolfertz, J, 1997
)
3.18
"Dobutamine is an inotropic agent with no apparent direct action on coronary resistance vessels in vivo."( Is calcium a coronary vasoconstrictor in vivo?
Crystal, GJ; Salem, MR; Zhou, X, 1998
)
1.02
"Dobutamine MRI is a reasonably good predictor of myocardial functional recovery after CABG. "( Dobutamine magnetic resonance imaging as a predictor of myocardial functional recovery after revascularisation.
Hillis, GS; McKiddie, FI; Redpath, TW; Trent, RJ; Waiter, GD; Walton, S, 2000
)
3.19
"Dobutamine is a beta1-, beta2-, and alpha1-adrenergic agonist."( Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
Bristow, MR; Lindenfeld, J; Lowes, BD, 1999
)
1.36
"Dobutamine cine MRI is a new diagnostic imaging technique in the pretreatment (revascularization) assessment of myocardial infarction patients. "( [Cine magnetic resonance with dobutamine following a myocardial infarct].
Giovagnoni, A; Ligabue, G; Modena, MG; Muia, N; Romagnoli, R; Rossi, R, 1999
)
2.03
"Dobutamine stress test is an alternative in patients with limited exercise capacity."( Dobutamine technetium-99m tetrofosmin SPECT imaging for the diagnosis of coronary artery disease in patients with limited exercise capacity.
Bax, JJ; Elhendy, A; Roelandt, JR; Sozzi, FB; Valkema, R; van Domburg, RT,
)
2.3
"Dobutamine is a beta 1 receptor agonist that exerts positive inotropic activity without significant alpha or beta 2 effect."( Use of dobutamine stress echocardiography in determination of myocardial viability.
Ijem, JK, 2001
)
1.49
"Dobutamine-based therapy is an attractive approach for the treatment of decompensated advanced heart failure, achieving comparable clinical efficacy to milrinone with a significantly reduced economic cost."( Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Albert, N; Haji, SA; Kelly, L; Knack, DL; Starling, RC; Yamani, MH; Young, JB, 2001
)
2.11
"Dobutamine is a commonly used inotropic treatment for CHF. "( Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
Elkayam, U; Ghali, JK; Horton, DP; Silver, MA, 2002
)
2.05
"Dobutamine is a synthetic ionotropic catecholamine commonly used to treat heart failure and shock. "( 3-O-methyldobutamine, a major metabolite of dobutamine in humans.
Blumer, JL; Webster, LT; Yan, M, 2002
)
2.16
"min dobutamine proved to be a potent inotropic agent causing almost no peripheral and relatively little positive chronotropic effects."( [Haemodynamic and vascular effects of dobutamine during and after open heart operations (author's transl)].
Hempelmann, G; Piepenbrock, S; Reichelt, W; Stegmann, T, 1979
)
1.01
"Dobutamine is a newly developed catecholamine reported to have minimal direct vascular effects relative to its inotropic activity and to have less chronotropic and arrhythmogenic properties than other catecholamines used in the treatment of low output states. "( Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure.
Bredakis, J; Gunner, RM; Loeb, HS, 1977
)
2.05
"Dobutamine is a newly developed catecholamine which has been shown to be of value in severe cardiomyopathic disease."( Comparative haemodynamic effects of dopamine and dobutamine in septic shock.
Carlet, J; Regnier, B; Safran, D; Teisseire, B, 1979
)
1.24
"Dobutamine therefore is a potent inotropic drug, with mild chronotropic and peripheral vascular effect and may be valuable in the management of severe heart failure not associated with hypotension."( Comparative haemodynamic effects of dobutamine and isoproterenol in man.
Bardet, J; Boschat, J; Bourdarias, JP; Ferreira, A; Rigaud, M; Rocha, P, 1977
)
1.25
"Dobutamine appeared to be an agonist at the beta 1- and beta 2-adrenoreceptors and at the myocardial alpha-adrenoreceptor. "( Hemodynamic effects of dobutamine in an intact animal model.
Banner, W; Dean, JM; Garrett, JS; Vernon, DD, 1992
)
2.04
"Dobutamine is a synthetic catecholamine that acts on alpha-1, beta-1 and beta-2 adrenergic receptors."( [Dobutamine: mechanisms of action and use in acute cardiovascular pathology].
Chopin, C; Dupuis, B; Vallet, B, 1991
)
1.91
"Dobutamine is a valuable pharmacological agent which can induce regional and global abnormalities of left ventricular function in patients with coronary artery disease during magnetic resonance imaging."( The cardiovascular effects of dobutamine assessed by magnetic resonance imaging.
Pennell, DJ; Underwood, SR, 1991
)
1.29
"Dobutamine is a commonly used positive inotrope for the short-term management of heart failure. "( Dobutamine: ten years later.
Bauman, JL; Danziger, LH; Dasta, JF; Majerus, TC; Ruffolo, RR, 1989
)
3.16
"Dobutamine is a potent inhibitor of uptake1 as well as of vesicular uptake; moreover, it easily diffuses into adrenergic nerve endings."( The effect of (+/-)-dobutamine on adrenergic nerve endings.
Burger, A; Fischer, P; Graefe, KH; Trendelenburg, U,
)
1.18
"Dobutamine seems to be an effective agent for the treatment of low cardiac output in asphyxiated neonates."( [Hemodynamic effects of dobutamine in asphyxiated newborn infants].
Devictor, D; Huault, G; Pariente, D; Verlhac, S,
)
1.16
"Dobutamine is a potent inotropic agent traditionally used for treatment of acute cardiac decompensation of congestive heart failure (CHF). "( Review of intermittent dobutamine infusions for congestive cardiomyopathy.
Marshall, LE; Thomas, RL; Watson, D, 1987
)
2.03
"Dobutamine is a sympathomimetic amine that was designed as an inotropic agent for use in congestive heart failure. "( The pharmacology of dobutamine.
Ruffolo, RR, 1987
)
2.04
"Dobutamine is a cardiac inotrope useful in the acute treatment of congestive heart failure. "( Use of intermittent dobutamine infusion in congestive heart failure.
Mauro, LS; Mauro, VF, 1986
)
2.04

Effects

Dobutamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses. Administration may be associated with supraventricular tachycardia and a protracted time to peak effect.

Dobutamine has been demonstrated to increase mesenteric blood flow during endotoxic shock. Its effects on mucosal blood flow especially in intestinal villi is not known. Dobutamine Hemodynamics has the potential to address these issues.

ExcerptReferenceRelevance
"Dobutamine has a half-life of 2 min and requires up to 10 min to achieve steady state. "( Effects of prolonging peak dobutamine dose during stress echocardiography.
Foster, GP; Picard, MH; Rose, GA; Weissman, NJ, 1997
)
2.04
"Dobutamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, sustained administration may be associated with supraventricular tachycardia and a protracted time to peak effect."( Temporal effects of an infusion of dobutamine hydrochloride in horses anesthetized with halothane.
Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1998
)
2.02
"Dobutamine has a favorable hemodynamic effect in mild-to-moderate pulmonary hypertension in lung transplant candidates."( [Hemodynamic changes during continuous infusion with dobutamine in candidates for lung transplantation. Lung Transplantation Group].
Coccia, C; Costa, MG; Della Rocca, G; Gasparetto, A; Pierconti, F; Pietropaoli, P; Pompei, L; Pugliese, F; Rendina, EA; Venuta, F; Vizza, CD, 1999
)
1.27
"Dobutamine-induced CS has also been much more frequently reported in patients from Asian descent with VSA."( Coronary artery spasm following dobutamine stress echocardiogram.
Judenherc Haouzi, A; Liszka, E; Schwartz, S, 2020
)
1.56
"Dobutamine has been used in septic shock for many years as an only inotrope, but its benefit has been questioned. "( Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation.
Hattori, K; Hattori, Y; Matsuda, N; Palikhe, S; Sakai, M; Suzuki, T; Tomita, K; Yamashita, S; Yoshimura, N, 2017
)
2.19
"Dobutamine (DOB) has been known to increase heart rate and the incidence of cardiac arrhythmias."( Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias.
Çavuşoglu, Y; Mert, GÖ; Mert, KU; Morrad, B; Mutlu, F; Tahmazov, S, 2017
)
1.43
"Dobutamine has significant inhibitory effects on gastric adenocarcinoma cells and may be used in neoadjuvant therapy not only for gastric cancer, but also for other tumors."( Inhibitory effects of dobutamine on human gastric adenocarcinoma.
Du, Q; Liang, JF; Wu, LN; Xiao, H; Zheng, HX, 2014
)
2.16
"Dobutamine (DB) has been recommended in combination with vasopressor therapy in septic shock, given its reported ability to improve mesenteric and microcirculatory perfusion. "( Effects of combination dobutamine and vasopressin therapy on microcirculatory blood flow in a porcine model of severe endotoxic shock.
Delaney, RR; Holt, DB; Uyehara, CF, 2011
)
2.12
"Dobutamine has been shown to improve right ventricular contractility and cardiac output in right ventricular failure. "( A novel hemodynamic observation: worsening of tricuspid regurgitation with dobutamine infusion during a hemodynamic study.
Glancy, DL; Hanna, EB; Jaligam, V,
)
1.8
"Dobutamine-stress CMR has emerged as a highly accurate and safe diagnostic modality [1-4]."( Diagnosis of coronary artery disease with dobutamine-stress MRI.
Kuijpers, D, 2005
)
1.31
"Dobutamine Hemodynamics has the potential to address these issues."( [Dobutamine hemodynamics for aortic stenosis with left ventricular dysfunction].
Gueret, P; Monin, JL, 2005
)
1.96
"Dobutamine stress MRI has emerged as a reliable and safe clinical alternative for noninvasive assessment of CAD."( Cardiac stress MR imaging with dobutamine.
Meyer, C; Schild, H; Sommer, T; Strach, K, 2006
)
1.34
"Dobutamine has the following properties, making it favorable for widespread usage: 1) ability to be given safely in a peripheral vein, 2) rapid onset, and 3) short duration of action."( A comparison of dobutamine infusion and supine bicycle exercise for radionuclide cardiac stress testing.
Barnes, WE; Eastman, G; Freeman, ML; Kaplan, E; Loeb, HS; Mason, J; Palac, R; Virupannavar, S, 1984
)
1.33
"Dobutamine has not yet been shown to have significant advantages over other inotropes and requires further examination."( Inotropic drugs in acute circulatory failure.
Herbert, P; Tinker, J, 1980
)
0.98
"Dobutamine has less vasopressor activity than norepinephrine and dopamine, and should not be the primary treatment in conditions characterized by marked hypotension and shock."( Drugs five years later. Dobutamine.
Leier, CV; Unverferth, DV, 1983
)
1.29
"Dobutamine has the advantage of being a single agent and is therefore easier to administer."( Dobutamine therapy in acute myocardial infarction.
Keung, EC; LeJemtel, TH; Ribner, HS; Schwartz, WJ; Siskind, SJ; Sonneblick, EH, 1981
)
2.43
"Dobutamine has been shown to increase heart rate in a dose-related fashion in animals and in humans."( Electrophysiologic and proarrhythmic effects of intravenous inotropic agents.
Borzak, S; Patel, R; Tisdale, JE; Webb, CR; Zarowitz, BJ,
)
0.85
"Dobutamine has become the inotropic agent of choice to increase DO2 to the tissues."( Inotropic agents.
Preiser, JC; Vincent, JL, 1993
)
1.01
"Dobutamine has been proposed as a means of disclosing a pathologic oxygen supply (DO2) dependency in critically ill patients. "( Effects of dobutamine on oxygen consumption in septic patients. Direct versus indirect determinations.
Berre, J; De Backer, D; Kahn, RJ; Moraine, JJ; Vincent, JL, 1994
)
2.12
"1. Dobutamine has been used to study the relationship between oxygen consumption (VO2) and oxygen delivery (DO2) in critically ill patients, but this has led to concerns that it could consistently increase VO2 in all patients. "( Effects of dobutamine on the relationship between oxygen consumption and delivery in healthy volunteers: comparison with sodium nitroprusside.
Berre, J; De Backer, D; Melot, C; Moraine, JJ; Vanfraechem, J; Vincent, JL, 1996
)
1.31
"The dobutamine has been given while monitoring systemic blood pressure, electrocardiography and echocardiography in steps of 10 mcg/kg/min' per 3 min' up to a maximum of 40 mcg/kg/min'."( [Comparison of the echo-dobutamine-atropine test and ergometric test in the diagnosis of coronary disease].
Adamo, M; Americo, L; Andolina, S; Ascione, A; Bonnì, G; Castello, A; Orlando, G; Sarullo, FM; Schicchi, R; Schillaci, AM; Schirò, M, 1996
)
1.08
"Dobutamine has a half-life of 2 min and requires up to 10 min to achieve steady state. "( Effects of prolonging peak dobutamine dose during stress echocardiography.
Foster, GP; Picard, MH; Rose, GA; Weissman, NJ, 1997
)
2.04
"Dobutamine has been demonstrated to increase mesenteric blood flow during endotoxic shock; however, its effects on mucosal blood flow especially in intestinal villi is not known."( Dobutamine maintains intestinal villus blood flow during normotensive endotoxemia: an intravital microscopic study in the rat.
Martin, E; Schmidt, H; Secchi, A; Wellmann, R, 1997
)
2.46
"Dobutamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, sustained administration may be associated with supraventricular tachycardia and a protracted time to peak effect."( Temporal effects of an infusion of dobutamine hydrochloride in horses anesthetized with halothane.
Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1998
)
2.02
"Dobutamine has marketing authorization in France for stress-echocardiography and is widely used in clinical practice outside research protocols."( [Myocardial viability. Myocardial viability post-infarct: contribution of dobutamine-echography].
Duval, AM; Gueret, P; Monin, JL, 1998
)
1.25
"Dobutamine has a favorable hemodynamic effect in mild-to-moderate pulmonary hypertension in lung transplant candidates."( [Hemodynamic changes during continuous infusion with dobutamine in candidates for lung transplantation. Lung Transplantation Group].
Coccia, C; Costa, MG; Della Rocca, G; Gasparetto, A; Pierconti, F; Pietropaoli, P; Pompei, L; Pugliese, F; Rendina, EA; Venuta, F; Vizza, CD, 1999
)
1.27
"Dobutamine has positive inotropic and chronotropic effects and is commonly used in patients who cannot exercise or achieve an adequate heart rate response with exercise."( Recent advances in dobutamine stress echocardiography.
O'Brien, TX; Usher, BW, 2000
)
1.36
"Dobutamine echo has satisfactory sensitivity, excellent specificity, and high diagnostic accuracy for the detection of viable dyssynergic myocardium."( [Assessment of myocardial vitality with dobutamine echocardiography: current review].
Flachskampf, FA; Nixdorff, U; Völler, H, 2000
)
1.3
"Dobutamine infusion has been proposed to increase splanchnic blood flow in septic conditions, but its' effects on liver blood flow and metabolism have not been well defined. "( Effects of dobutamine on hepato-splanchnic hemodynamics in an experimental model of hyperdynamic endotoxic shock.
Borgers, M; Cherkhaoui, S; De Backer, D; Vincent, JL; Zhang, H, 2001
)
2.14
"Dobutamine has no direct effect upon coronary vascular tone."( Haemodynamic effects of dobutamine with special reference to myocardial blood flow. A comparison with dopamine and isoprenaline.
Ead, H; Spurrell, R; Stephens, J, 1979
)
1.29
"Dobutamine has potent calorigenic effects; demonstration of a positive correlation between VO2 and DO2 after infusion of dobutamine does not necessarily imply an underlying tissue oxygen debt."( Effect of dobutamine on oxygen supply and uptake in healthy volunteers.
Bhatt, SB; Hutchinson, RC; Mak, M; Oh, TE; Tomlinson, B, 1992
)
1.41
"Dobutamine has favorable properties for the pharmacologic manipulation of myocardial oxygen demand in the provocation of ischemia during the investigation of coronary artery disease. "( Dobutamine thallium myocardial perfusion tomography.
Ell, PJ; Pennell, DJ; Swanton, RH; Underwood, SR; Walker, JM, 1991
)
3.17
"Dobutamine has been shown to exert disparate clinical effects in patients with cardiomyopathy and heart failure. "( The effect of dobutamine on myocardial performance and high-energy phosphate metabolism at different stages of heart failure in cardiomyopathic hamsters: a 31P MRS study.
Buser, PT; Camacho, SA; Higgins, CB; Jasmin, G; Parmley, WW; Wikman-Coffelt, J; Wu, ST, 1989
)
2.08
"Dobutamine has been used successfully in several circumstances, such as after cardiac surgery, in patients with myocardial infarction, and in various shock states."( Dobutamine: ten years later.
Bauman, JL; Danziger, LH; Dasta, JF; Majerus, TC; Ruffolo, RR, 1989
)
2.44
"Dobutamine has the capacity to stimulate beta 1-, beta 2-, and alpha 1-adrenoceptors in the cardiovascular system at doses that approximate those used clinically."( The pharmacology of dobutamine.
Ruffolo, RR, 1987
)
1.32

Actions

Dobutamine causes an increase not only in the mean gradient, but also in the valve area. A dobutamine-induced increase in rate pressure product was proportional to an increase in myocardial blood flow. Dobutamine failed to increase cardiac and stroke index significantly.

ExcerptReferenceRelevance
"Dobutamine, a common cause of HSM, was administered to 12 patients (57%)."( Characteristics of patients with advanced heart failure having eosinophilic infiltration of the myocardium in the recent era.
C Marboe, C; Mancini, D; Sugiyama Kato, T; Yoshizawa, S, 2013
)
1.11
"Dobutamine does increase the HR and has some deleterious effects on myocardium."( Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
Cavusoglu, Y; Mert, U; Morrad, B; Mutlu, F; Nadir, A; Ulus, T, 2015
)
1.43
"Dobutamine did not increase carotid arterial compliance."( The effect of dobutamine without and with L-arginine on arterial compliance in heart failure patients.
Lage, SG; Lagudis, S; Mansur, AJ; Medeiros, CC; Vieira, ML; Yamada, AT, 2009
)
1.43
"Dobutamine did not increase stroke volumes significantly despite slightly enhanced contractility (end-systolic pressure-volume relation)."( Pulmonary vascular resistance, collateral flow, and ventricular function in patients with a Fontan circulation at rest and during dobutamine stress.
Berger, F; Ewert, P; Kuehne, T; Lunze, K; Maarouf, N; Ovroutski, S; Rahmanzadeh, P; Schmitt, B; Steendijk, P, 2010
)
1.29
"The dobutamine-induced increase in ejection fraction (contractile reserve [CR]) was measured, and the most mechanically delayed segment was identified to classify patients into 2 groups."( Usefulness of low-dose dobutamine echocardiography to predict response and outcome in patients undergoing cardiac resynchronization therapy.
Altman, RK; Chen-Tournoux, AA; McCarty, D; Orencole, M; Park, MY; Picard, MH; Riedl, L; Singh, JP; Tournoux, FB, 2011
)
1.16
"Dobutamine causes an increase in cardiac output (CO) by augmenting stroke volume (SV) through enhanced left ventricular contractility and by decreasing systemic vascular resistance. "( Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers.
Ahonen, J; Aranko, K; Iivanainen, A; Maunuksela, EL; Olkkola, KT; Paloheimo, M, 2008
)
2.04
"Dobutamine caused a 28% increase in MBV, responsible for 32% of the decrease in the total MVR, but the increase in MBF arose mainly from the increase in b (deltabeta/deltaA=5.9)."( [Assessment of direct effects of dobutamine on coronary microcirculation with myocardial contrast echocardiography: comparison with adenosine].
Bin, JP; Kaul, S; Le, DE; Liu, YL; Yang, F; Zha, DG, 2008
)
1.35
"With dobutamine this increase was matched by a similar increase in coronary blood flow; however, failure of the expected increase in coronary blood flow with dopamine suggested coronary constriction."( Dobutamine and dopamine after cardiac surgery: greater augmentation of myocardial blood flow with dobutamine.
Alderman, EL; Daughters, GT; Derby, G; Fowler, MB; Ingels, NB; Miller, DC; Mitchell, RS; Oesterle, SN; Stinson, EB, 1984
)
2.17
"The dobutamine-induced increase in cardiac index remained virtually unchanged."( Preliminary evidence for the mechanism underlying the development of tolerance to prazosin in congestive heart failure: the alpha-agonistic properties of dobutamine unmasked by prazosin treatment.
Giesen, G; Kersting, F; Kupp, M, 1993
)
0.96
"Dobutamine was used to increase cardiac output, thereby directly varying TO2 under conditions of constant O2 demand. "( Effects of dobutamine on oxygen transport and consumption in the adult respiratory distress syndrome.
Dantzker, DR; Gutierrez, G; Krachman, SL; Lodato, RF; Morice, R, 1994
)
2.12
"Dobutamine failed to increase MAP above 30 mm Hg in six infants out of 10, whereas dopamine succeeded in all 10 infants."( Response to dobutamine and dopamine in the hypotensive very preterm infant.
Lefèvre, M; Maingueneau, C; Mouzard, A; Rozé, JC; Tohier, C, 1993
)
1.39
"Dobutamine elicited an increase (p < 0.01) in the total QRS variance, with significantly higher (p < 0.001) total variance in patients than in controls."( Beat-to-beat QRS amplitude variability during dobutamine infusion in patients with coronary artery disease.
Hagerman, I; Nowak, J; Nyquist, O; Svedenhag, J; Sylvén, C,
)
1.11
"Dobutamine induced an increase of cardiac index (2.0 +/- 0.1 to 2.9 +/- 0.21/min/m2; p < 0.01; mean +/- SEM) and heart rate (96 +/- 6 to 117 +/- 5 min-1; p < 0.05) while mean arterial pressure (75 +/- 2 to 71 +/- 4 mm Hg) and pulmonary capillary wedge pressure (21 +/- 2 to 19 +/- 2 mm Hg) hardly changed."( [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
Meissner, A; Schmelzle, T; Simon, R, 1996
)
1.23
"Dobutamine results in an increase not only in the mean gradient, but also in the valve area."( Dobutamine stress Doppler hemodynamics in patients with aortic stenosis: feasibility, safety, and surgical correlations.
Lin, SS; Pascoe, R; Pellikka, PA; Roger, VL; Seward, JB, 1998
)
2.46
"A dobutamine-induced increase in rate pressure product was proportional to an increase in myocardial blood flow in non-ischaemic regions. "( [Dobutamine-induced changes in the myocardial blood flow in patients with coronary heart diseases. A quantitative analysis using [15O] H2O positron emission tomography].
Baer, FM; Erdmann, E; Moka, D; Schicha, H; Schneider, CA; Voth, E; Wagner, R, 2000
)
1.94
"Dobutamine caused an increase in MDV (P =.0001) and epsilon(s) (P =.09) above baseline values. "( Use of peak systolic strain as an index of regional left ventricular function: comparison with tissue Doppler velocity during dobutamine stress and myocardial ischemia.
Armstrong, G; Cardon, L; Fukamachi, K; Marwick, T; Olstad, B; Pasquet, A, 2000
)
1.96
"Dobutamine produced an increase in cardiac index (2.4-3.3 l/min/m2, P=0.0001) only at doses that are not typically used to treat heart failure (15-20 microg/kg/min)."( Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
Bristow, MR; Eichhorn, EJ; Gilbert, EM; Lowes, BD; Tsvetkova, T, 2001
)
1.37
"Dobutamine failed to increase cardiac and stroke index significantly, but increased mean aortic pressure distinctly due to an elevated total peripheral resistance."( [The haemodynamic effects of dobutamine and dopamine in patients with coronary artery disease. A study performed under general anaesthesia (author's transl)].
Brückner, JB; Hess, W; Schmidt, D; Tarnow, J; von Faber du Faur, J, 1979
)
1.27
"Dobutamine and dopamine increase myocardial blood flow and oxygen consumption."( [A comparison of cardiovascular effects of dobutamine and dopamine (author's transl)].
Brückner, JB; Hess, W; Schmidt, D; Schweichel, E; Tarnow, J, 1977
)
1.24
"Dobutamine did not cause a significant increase in hepatic arterial blood flow."( The effect of dobutamine on hepatic blood flow and oxygen supply-uptake ratio during enflurane nitrous oxide anesthesia in humans undergoing liver resection.
Ito, T; Kainuma, M; Kimura, N; Kurokawa, T; Nakashima, K; Nonami, T; Shimada, Y, 1992
)
1.37
"Dobutamine produced an increase in systolic arterial pressure of 23% after 2 hours, maintaining increased values of approximately 20% during the observation period."( [Enoximone in postoperative "low-output syndrome"--comparison with dobutamine].
Darwisch, M; Dieterich, HA; Köllner, V; Orellano, L, 1991
)
1.24
"Dobutamine is known to increase leg blood flow during exercise in patients with heart failure. "( Effect of dobutamine on skeletal muscle metabolism in patients with congestive heart failure.
Chance, B; Ferraro, N; Mancini, DM; Schwartz, M; Seestedt, R; Wilson, JR, 1990
)
2.12
"Dobutamine did not produce coronary vasoconstriction at any dose tested."( Alpha-adrenergic effects of dopamine and dobutamine on the coronary circulation.
Bache, RJ; Chen, DG; Dai, XZ, 1989
)
1.26
"Dobutamine is used to increase cardiac output in infants and children with circulatory failure."( Dopamine and dobutamine in pediatric therapy.
Bhatt-Mehta, V; Nahata, MC, 1989
)
1.37
"Dobutamine alone did not cause a statistically significant increase in stroke index, stroke work index, cardiac index and ejection fraction, although pulmonary capillary wedge pressure and right atrial pressure fell (P less than 0.05)."( Synergistic effect of captopril and dobutamine on left ventricular pressure-volume and pressure-shortening relations in severe cardiac failure.
Halon, DA; Hardoff, R; Lewis, BS; Merdler, A; Rodeanu, ME; Saggie, Y, 1988
)
1.27
"Only dobutamine was found to increase coronary outflow by 49%, 117% and 137% at increases in dp/dt of 71%, 118% and 173%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)"( Comparison of the cardiodynamic and metabolic effects of dobutamine with those of norepinephrine and dopamine in the dog isolated heart.
Fawaz, G; Jabbour, K; Simaan, JA, 1988
)
0.98
"Dobutamine did not produce a significant change in the pulmonary capillary wedge pressure (27 +/- 5 to 24 +/- 6 mm Hg, NS) nor in mean arterial pressure (83 +/- 9 to 86 +/- 10 mm Hg, NS), but caused a significant rise in heart rate (85 +/- 16 to 99 +/- 17 beats/min, p = .001) and in myocardial oxygen consumption (8.7 +/- 2.1 to 11.1 +/- 3.8 ml O2/min, p = .03)."( Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure.
Baim, DS; Lanoue, AS; Monrad, ES; Smith, HS, 1986
)
1.38
"The dobutamine-induced increase of adenylate cyclase activity is more prominent in the renal pelvis including the pacemaker region than in the ureter that is non-pacemaker region in the upper urinary tract."( Effect of dobutamine on adenylate cyclase activity in rabbit renal pelvis and ureter.
Kondo, S; Morita, T; Tashima, Y; Terui, M; Tsuchida, S, 1986
)
1.15

Treatment

Dobutamine treatment may contribute to circulating TNF-α and dopamine to IL-6. In dobutamine-treated animals, cardiac index, DO2, and VO2 were better maintained for any intrapericardial pressure than in the other groups.

ExcerptReferenceRelevance
"Dobutamine treatment was infused at a rate of 4 µg·kg"( The effect of dobutamine treatment on salvage of digital replantation and revascularization.
Dadaci, M; Ince, B; Ismayilzade, M; Uyanik, O; Yildirim, MEC, 2023
)
1.99
"Dobutamine-treated animals had lower perfusion pressures and blood pH compared with epinephrine + milrinone and dopamine + milrinone groups."( Inotropic therapy for right ventricular failure in newborn piglets: effect on contractility, hemodynamics, and interventricular interaction.
Frederiksen, CA; Heiberg, J; Hyldebrandt, JA; Ravn, HB; Redington, AN; Rothmann, S; Schmidt, MR, 2014
)
1.12
"Dobutamine treatment proved to have significant effects on hemodynamic perturbations only in the group treated at the rate of 20 microg/kg/min."( Beneficial effects of high dobutamine doses on hemodynamic perturbations induced by Buthus occitanus tunetanus venom in rats.
Bouaziz, M; Hakim, A; Kallel, H; Kassis, M; Sahnoun, Z; Zeghal, KM, 2009
)
1.37
"Dobutamine treatment may contribute to circulating TNF-α and dopamine to IL-6, independently of activated neutrophils."( Vasopressors and inotropes in the treatment of human septic shock: effect on innate immunity?
Groeneveld, AB; Hartemink, KJ, 2012
)
1.1
"In dobutamine-treated animals, cardiac index, DO2, and VO2 were better maintained for any intrapericardial pressure than in the other groups."( Effects of dobutamine and norepinephrine on oxygen availability in tamponade-induced stagnant hypoxia: a prospective, randomized, controlled study.
Spapen, H; Vincent, JL; Zhang, H, 1994
)
1.19
"Dobutamine-treated animals had a higher cardiac index compared with control animals (218 +/- 22 vs."( Effects of dobutamine on splanchnic tissue perfusion during partial superior mesenteric artery occlusion.
Alhava, E; Hartikainen, J; Heino, A; Koski, EM; Merasto, ME; Takala, J; Tenhunen, J, 2000
)
1.42
"Dobutamine treatment was not associated with significant improvements in pump or muscle function in control or hypertensive hearts."( Effects of chronic dobutamine administration on hearts of normal and hypertensive rats.
Buttrick, P; Factor, S; Geenen, D; Malhotra, A; Scheuer, J, 1988
)
1.32
"Four treatments (dobutamine at 4 and 8 microg/kg/min and norepinephrine at 0.3 and 1 microg/kg/min) were administered in random order via constant rate infusion over 15 minutes, followed by repeat measurements of cardiopulmonary values and a 20-minute washout period."( Cardiopulmonary effects of dobutamine and norepinephrine infusion in healthy anesthetized alpacas.
Bedenice, D; Hawley, AT; Lascola, KM; Rozanski, EA; Vincent, CJ, 2009
)
0.98
"Treatment with dobutamine improves post-resuscitation left ventricular function."( Post-resuscitation right ventricular dysfunction: delineation and treatment with dobutamine.
Berg, RA; Ewy, GA; Hilwig, RW; Kern, KB; Meyer, RJ, 2002
)
0.88
"Treatment with dobutamine was associated with a significantly greater increase in left ventricular output in the single study reporting that outcome."( Dopamine versus dobutamine for hypotensive preterm infants.
Shaw, NJ; Subhedar, NV, 2003
)
1
"Pretreatment with dobutamine induced HO-1 in pericentral hepatocytes and improved PDR(ICG) (Vehicle/Shock: 11.7 +/- 8.12%/min vs. "( Dobutamine improves liver function after hemorrhagic shock through induction of heme oxygenase-1.
Bauer, I; Kreuer, S; Kubulus, D; Pradarutti, S; Raddatz, A; Rensing, H; Winning, J; Wolf, B, 2006
)
2.11
"Pretreatment with dobutamine might be a potential means of pharmacologic preconditioning before ischemia-reperfusion of the liver."( Dobutamine improves liver function after hemorrhagic shock through induction of heme oxygenase-1.
Bauer, I; Kreuer, S; Kubulus, D; Pradarutti, S; Raddatz, A; Rensing, H; Winning, J; Wolf, B, 2006
)
2.1
"3. Treatment with dobutamine (10(-6) M) produced no significant change in 3 beta-HSD mRNA accumulation."( Alterations in 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) mRNA accumulation induced by beta-adrenergic stimulation in cultured porcine granulosa cells.
Chedrese, PJ; Juorio, AV; Li, XM; Murphy, BD, 1993
)
0.61
"Treatment with Dobutamine and antiarrythmics led to a rapid decrease of transaminase levels and recovery in liver function."( Increased transaminases in psychiatry: a case report.
Adler, M; Bourgeois, N; Bourgeois, V; Devière, J; el Nawar, A; Le Moine, O; Nouar, E; Peny, MO,
)
0.47
"Treatment with dobutamine (DBT), a beta 1-agonist, (30 mg/kg twice a day for 4 days) produced a significant enlargement of the parotid gland just as in the ISP-treated rats."( Hypertrophy and dysfunction of parotid gland induced by chronic stimulation of beta 1-adrenergic receptors.
Ohshika, H; Suzuki, Y, 1985
)
0.61

Toxicity

Dobutamine/atropine echo stress test may be considered a safe test for the evaluation of the presence and severity of coronary artery disease. There were less adverse effects including hypokalemia, hypotension and ventricular premature beats in levosimendan group than in the dobutamine group.

ExcerptReferenceRelevance
"In 95% of cases the test was stopped at the achievement of a target end point: wall motion abnormalities (60%), significant ECG changes (5%), 85% of the age-predicted maximal heart rate (13%), maximal dose (17%); only in 5% of cases a limiting side effect requiring a premature interruption of the test occurred: hypertension (systolic blood pressure over 240 mm Hg and/or diastolic over 120 mm Hg) (2%); symptomatic hypotension (0."( [The side effects and safety of the echo-dobutamine test. The experience with 373 patients].
Diotallevi, P; Fetiveau, R; Lanzarini, L; Montemartini, C; Mussini, MF; Poli, A; Previtali, M, 1995
)
0.56
" Non limiting side effects, in particular cardiac arrhythmias and systolic hypotension, are usually well tolerated and not associated with the occurrence of myocardial ischemia or left ventricular disfunction; thus, dobutamine echo stress test may be considered a safe test for the evaluation of the presence and severity of coronary artery disease both in patients with a previous or recent myocardial infarction and in patients without myocardial infarction."( [The side effects and safety of the echo-dobutamine test. The experience with 373 patients].
Diotallevi, P; Fetiveau, R; Lanzarini, L; Montemartini, C; Mussini, MF; Poli, A; Previtali, M, 1995
)
0.74
"Dobutamine-atropine stress echocardiography is a feasible and safe test for assessing elderly patients with suspected and/or proven coronary artery disease, providing useful prognostic information for perioperative and late cardiac risk with relatively few side effects."( Dobutamine-atropine stress echocardiography in elderly patients unable to perform an exercise test. Hemodynamic characteristics, safety, and prognostic value.
Arnese, M; Boersma, E; Cornel, JH; Fioretti, PM; Poldermans, D; Roelandt, JR; ten Cate, FJ; Thomson, IR; van Urk, H,
)
3.02
" In conclusion, dobutamine and dipyridamole-MRI are well tolerated and safe non-exercise dependent tests for detection and localization of hemodynamically significant coronary artery stenoses with a similar diagnostic accuracy but with a better control of stress intensity and duration provided by dobutamine."( [Dobutamine versus dipyridamole magnetic resonance tomography: safety and sensitivity in the detection of coronary stenoses].
Baer, FM; Hilger, HH; Schicha, H; Sechtem, U; Smolarz, K; Theissen, P; Voth, E, 1993
)
1.54
" No major side effect occurred during the entire study and peak dose (40 micrograms."( Diagnosis of coronary artery disease in elderly patients: safety and efficacy of dobutamine echocardiography.
Baudhuin, T; D'Hondt, AM; Detry, JM; Marwick, T; Melin, J; Wijns, W, 1993
)
0.51
" From these data, high dose dobutamine stress test is useful and relatively safe stress method for diagnosis of coronary disease."( [Usefulness and safety of dobutamine stress thallium myocardial scintigraphy].
Araki, Y; Horiuchi, K; Imai, K; Ozawa, Y; Saito, S; Yasugi, T, 1993
)
0.88
" Dobutamine thallium-201 myocardial perfusion tomography is a safe procedure in patients with asthma."( Safety of dobutamine stress for thallium-201 myocardial perfusion tomography in patients with asthma.
Ell, PJ; Pennell, DJ; Underwood, SR, 1993
)
1.6
" Records were reviewed to determine whether there was any evidence of aneurysm rupture or adverse vascular events as a result of the stress test."( Safety of performing dobutamine stress echocardiography in patients with abdominal aortic aneurysm > or = 4 cm in diameter.
Oh, JK; Pellikka, PA; Roger, VL; Seward, JB; Tajik, AJ, 1996
)
0.61
" The authors consider dobutamine stress echocardiography a safe test which is well tolerated by the majority of patients and there is a minimum of side-effects."( [Analysis of adverse effects of dobutamine stress echocardiography].
Chaloupka, V; Elbl, L; Janousek, S; Nehyba, S, 1996
)
0.89
"These echocardiographic stress tests proved safe and well tolerated."( Stress echocardiography in elderly patients with coronary artery disease: applicability, safety and prognostic value of dobutamine and adenosine echocardiography in elderly patients.
Anthopoulos, LP; Bonou, MS; Kardara, DN; Kardaras, FG; Kranidis, AI; Margaris, NG; Sideris, AM; Sioras, EP, 1996
)
0.5
"When done with the necessary caution, dobutamine myocardial perfusion imaging is a safe diagnostic test, although side effects are common."( Tolerance, hemodynamic changes, and safety of dobutamine stress perfusion imaging.
Dakik, HA; Vempathy, H; Verani, MS,
)
0.66
" Dobutamine proved to be a very sensitive method to detect clinical and subclinical cardiac dysfunction in patients post anthracycline chemotherapy and questions the concept of a safe dose."( Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors.
Benoit, Y; De Wolf, D; Matthijs, D; Maurus, R; Otten, J; Suys, B; Verhaaren, H, 1996
)
2.65
"This study sought to document the safety of dobutamine stress echocardiography as it has evolved at a single center and to define predictors of adverse events."( Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years.
Marwick, TH; Secknus, MA, 1997
)
0.93
" Dobutamine-atropine stress echocardiography is a safe and feasible method for the assessment of hypertensive patients referred for evaluation of myocardial ischemia."( Safety and feasibility of dobutamine-atropine stress testing in hypertensive patients.
Elhendy, A; Fioretti, PM; Geleijnse, ML; Ibrahim, MM; Roelandt, JR; van Domburg, RT, 1997
)
1.51
" Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events."( Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997
)
0.3
" The purpose of this study was to analyse prospectively the safety, adverse event profile and complication rate of DSE."( Safety of dobutamine stress echocardiography in 474 consecutive studies.
Codd, MB; Hennessy, TG; Kane, G; McCann, HA; McCarthy, C; Sugrue, DD,
)
0.53
" DSE is a useful, feasible and safe exercise-independent stress modality for assessing the presence, localization and extent of CAD."( Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography.
Fioretti, PM; Geleijnse, ML; Roelandt, JR, 1997
)
0.54
"Dobutamine/atropine echo stress test may be considered a safe test for the evaluation of the presence and severity of coronary artery disease in patients with a previous or recent myocardial infarction."( [Feasibility and safety of dobutamine/atropine echocardiography following acute myocardial infarct].
Biferali, F; Ciavatti, M; Falcone, M; Palamara, A; Paventi, S, 1997
)
2.04
"DASE is a safe and feasible method for the study of patients with suspected or known coronary artery disease."( [Safety and feasibility of dobutamine-atropine stress echocardiography].
Andrade, JL; Beneti, LP; Beraldo, A; dos Santos, FC; Duprat, R; Gil, MA; Martinez, E; Mathias Júnior, W, 1997
)
0.59
"Echo-dobutamine stress test seems to be a very safe and reliable test for unmasking myocardial ischemia or viability in known or suspected coronary artery disease."( RITED (Registro Italiano Test Eco-Dobutamina): side effects and complications of echo-dobutamine stress test in 3041 examinations.
Gentile, F; Mantero, A; Morabito, A; Pezzano, A; Ravizza, P, 1998
)
1.04
" Outpatient DSE is safe when supervised by RN sonographers."( Safety of dobutamine stress echocardiography supervised by registered nurse sonographers.
Bremer, ML; Miller, FA; Monahan, KH; Pellikka, PA; Seward, JB; Stussy, VL, 1998
)
0.7
" Patients with AF had an increased chronotropic response to dobutamine, but there were no adverse effects and no evidence that the lower doses of dobutamine typically given to patients with AF were insufficient to induce ischemia."( Chronotropic response, safety, and accuracy of dobutamine stress echocardiography in patients with atrial fibrillation and known or suspected coronary artery disease.
Attenhofer Jost, CH; Hobday, TJ; Miller, FA; Oh, JK; Pellikka, PA; Seward, JB, 1998
)
0.8
"In a large group of patients with severe left ventricular dysfunction, dobutamine stress echocardiography is feasible and safe in 186/200 (93%); the addition of atropine was necessary in 34% to assess myocardial viability."( Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction.
Bax, JJ; Boersma, E; Breburda, CS; Cornel, JH; Fioretti, PM; Poldermans, D; Rambaldi, R; Roelandt, JR; Thomson, IR; Valkema, R, 1998
)
0.79
" We conclude that dobutamine-atropine stress echocardiography is a reasonably safe method for detection of coronary artery disease in the hospital or in an ambulatory basis."( Safety of dobutamine-atropine stress echocardiography: A prospective experience of 4,033 consecutive studies.
Andrade, JL; Arruda, A; Arruda, AL; Campos, O; Carvalho, AC; Gil, M; Mathias, W; Mattos, E; Osório, A; Santos, FC, 1999
)
1.04
" Adverse effects during testing are relatively frequent, precluding the achievement of a diagnostic end-point in about 5 to 10% of tests."( Dobutamine stress echocardiography: safety in diagnosing coronary artery disease.
Adamo, E; Lattanzi, F; Picano, E; Varga, A, 2000
)
1.75
"The purpose of the study was to assess the safety, adverse effects and complications of the dobutamine stress echocardiography (ED)."( [Side effects during dobutamine stress echocardiography: analysis of 582 studies].
Demczuk, M; Drozdz, J; Flasiński, J; Gackowski, A; Gasior, Z; Kleinrok, A; Krzymińska, E; Płońska, E; Sas, M; Sieńko, A; Swiatkiewicz, I; Szwed, H; Szyszka, A, 1999
)
0.84
" The exercise test is an extremely safe procedure, with an event rate similar to other recent surveys."( A survey of exercise testing: methods, utilization, interpretation, and safety in the VAHCS.
Froelicher, VF; Myers, J; Umann, T; Voodi, L,
)
0.13
"In patients with a high pretest probability of coronary artery disease (CAD), a continuous infusion of high-dose dobutamine is a feasible and safe method for performing a dobutamine stress test."( Accelerated dobutamine stress testing: safety and feasibility in patients with known or suspected coronary artery disease.
Fernicola, DJ; Greenberg, MD; Little, R; Lu, D; Malik, Q; Weissman, NJ, 2001
)
0.9
"Dobutamine stress myocardial perfusion imaging is a safe and feasible method for evaluation of coronary artery disease in heart transplant recipients."( Impact of heart transplantation on the safety and feasibility of the dobutamine stress test.
Balk, AH; Bax, JJ; Elhendy, A; Maat, LP; Poldermans, D; Roelandt, JR; Sozzi, FB; van Domburg, RT; Vantrimpont, P, 2001
)
1.99
"The stress echocardiography is a safe technique, but not harmless."( [Evaluation of the safety of stress echocardiography in Spain and Portugal].
Alonso-Orcajo, N; Branco, L; Corral Fernández, F; Garrote Coloma, C; Iglesias-Garriz, I; Picano, E; Rodríguez García, MA, 2001
)
0.31
" The most common side effect during the infusion was headache (9 of 12 tezosentan-treated patients and both dobutamine-treated patients)."( A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure.
Durand, JB; Kobrin, I; Nagueh, S; Pratt, C; Torre-Amione, G; Vooletich, MT, 2001
)
0.52
"Based on this limited series of patients, we believe that it may be safe to use HA in patients treated with GDC for SAH."( Safety of hemodynamic augmentation in patients treated with Guglielmi detachable coils after acute aneurysmal subarachnoid hemorrhage.
Aiyagari, V; Cross , DT; Dacey , RG; Deibert, E; Diringer, MN, 2001
)
0.31
" The incidence of adverse events in the patients treated with nitroprusside was similar to that in those treated with dobutamine (20% vs."( Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome.
Capomolla, S; Caporotondi, A; Cobelli, F; Febo, O; Gnemmi, M; Guazzotti, G; La Rovere, MT; Maestri, R; Mortara, A; Opasich, C; Pinna, GD; Vona, M, 2001
)
0.84
" Although vasodilator stress modalities should intuitively be the non-exercise stress technique of choice in these patients, stress echocardiography with the use of dobutamine appears to be safe and represents an acceptable option when used for diagnostic purposes or preoperative risk stratification in this patient population."( Safety of dobutamine stress echocardiography in patients with unruptured intracranial aneurysms.
Barnett, G; Griffin, BP; Novaro, GM; Pellikka, PA; Takhtehchian, DS, 2002
)
0.91
" DSE is a safe and feasible method for evaluating myocardial ischemia in patients with an ICD."( Safety and feasibility of dobutamine stress echocardiography in patients with implantable cardioverter defibrillators.
Elhendy, A; Porter, TR; Windle, J, 2003
)
0.62
" Adverse side effects do not relate to stress-induced ischemia or atropine addition."( Safety of dobutamine stress echocardiography in patients with aortic stenosis.
Bax, JJ; Bountioukos, M; Kertai, MD; Krenning, BJ; Poldermans, D; Rizzello, V; Roelandt, JR; Schinkel, AF; Vourvouri, EC, 2003
)
0.72
" These findings suggest that transplantation of unmanipulated autologous bone marrow into scar tissue of the human heart is safe and enhances cardiac function only when used in combination with myocardial revascularization."( Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans.
Bell, PR; Chin, D; Davies, J; Galiñanes, M; Loubani, M; Pasi, J, 2004
)
0.32
" Dobutamine CMR is safe and feasible in patients with suspicion of myocardial ischemia."( Dobutamine stress MRI. Part I. Safety and feasibility of dobutamine cardiovascular magnetic resonance in patients suspected of myocardial ischemia.
Janssen, CH; Kuijpers, D; Oudkerk, M; van Dijkman, PR, 2004
)
2.68
"004), no other difference in adverse effects was observed between patients >or= 70 and < 70 years."( Safety and cardiac chronotropic responsiveness to the early injection of atropine during dobutamine stress echocardiography in the elderly.
Fernandes, DR; Franchini Ramires, JA; Kowatsch, I; Lario, FC; Mathias, W; Sbano, JC; Tsutsui, JM, 2005
)
0.55
"Early atropine DSE is a safe strategy in the elderly resulting in lower incidence of minor adverse effects than with the conventional protocol."( Safety and cardiac chronotropic responsiveness to the early injection of atropine during dobutamine stress echocardiography in the elderly.
Fernandes, DR; Franchini Ramires, JA; Kowatsch, I; Lario, FC; Mathias, W; Sbano, JC; Tsutsui, JM, 2005
)
0.55
" The hemodynamic and adverse effects of RTCE were compared with 1,012 patients who underwent conventional dobutamine stress echocardiography (DSE) without contrast."( Safety of dobutamine stress real-time myocardial contrast echocardiography.
Elhendy, A; McGrain, AC; O'Leary, EL; Porter, TR; Tsutsui, JM; Xie, F, 2005
)
0.94
"Dobutamine stress RTCE appears to be a safe and feasible technique for evaluating patients with known or suspected CAD."( Safety of dobutamine stress real-time myocardial contrast echocardiography.
Elhendy, A; McGrain, AC; O'Leary, EL; Porter, TR; Tsutsui, JM; Xie, F, 2005
)
2.17
" In our study, DASE proved to be feasible and safe in octogenarians."( [Safety and feasibility of dobutamine-atropine stress echocardiography in octogenarian patients].
Abreu, JS; Diógenes, TC; Farias, AG; Morais, JM; Paes Júnior, JN, 2005
)
0.63
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In conclusion, stress echocardiography is a safe method in the real world, but serious complications may occur."( Safety of stress echocardiography (from the International Stress Echo Complication Registry).
Garcia, MA; Picano, E; Varga, A, 2006
)
0.33
" However, the protocol recommended for Dob-MPS is long and frequently associated with adverse effects."( Reduced adverse effects with an accelerated dobutamine stress protocol compared with the conventional protocol: a prospective, randomized myocardial perfusion scintigraphy study.
De Lorenzo, A; Issa, A; Leão Lima, Rde S, 2008
)
0.61
" We compared age, gender, coronary risk factors, history of MI or revascularization, Dob infusion and total stress times, maximal HR, percentage of maximal predicted HR, rate-pressure product, ST changes, MPS scores and incidence of adverse effects."( Reduced adverse effects with an accelerated dobutamine stress protocol compared with the conventional protocol: a prospective, randomized myocardial perfusion scintigraphy study.
De Lorenzo, A; Issa, A; Leão Lima, Rde S, 2008
)
0.61
"Early administration of atropine makes stress faster and reduces incidence of adverse effects, without reducing efficacy towards achieving the proposed goals."( Reduced adverse effects with an accelerated dobutamine stress protocol compared with the conventional protocol: a prospective, randomized myocardial perfusion scintigraphy study.
De Lorenzo, A; Issa, A; Leão Lima, Rde S, 2008
)
0.61
"This accelerated dobutamine-atropine stress echocardiography protocol is safe in a low-risk population and has a rate of complications similar to that reported for the standard protocol."( Safety and predictors of complications with a new accelerated dobutamine stress echocardiography protocol.
Arnold, R; Carnero, A; Fernández-Aviles, F; Gómez, I; Jimenez, D; Muñoz, AC; Ortega, JR; Pérez-Paredes, M; Pinedo, M; Rollán, MJ; San Román, JA; Sanz-Ruiz, R; Segura, F, 2008
)
0.93
" Our data demonstrate that a continous infusion of a single high dose of dobutamine is a safe and well tolerated method of performing stress echocardiography in patients with suspected or known coronary artery disease."( Feasibility, safety and tolerability of accelerated dobutamine stress echocardiography.
Manzara, C; Minardi, G; Pavaci, H; Pino, PG; Pulignano, G; Sordi, M, 2007
)
0.82
" Other observed adverse events included: intense headache, 52 (1%); intense back pain, 26 (0."( Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischaemia in 5250 studies.
Aggeli, C; Christoforatou, E; Giannopoulos, G; Marinos, G; Pitsavos, C; Roussakis, G; Stefanadis, C; Toli, C, 2008
)
0.58
"This report of safety data regarding stress-contrast echocardiography in a large series of subjects suggests that this is an exceptionally safe technique, given that in 5250 studies no study-related deaths or myocardial infarctions were encountered, whereas serious adverse events requiring hospitalisation were extremely rare (one in 2625 studies)."( Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischaemia in 5250 studies.
Aggeli, C; Christoforatou, E; Giannopoulos, G; Marinos, G; Pitsavos, C; Roussakis, G; Stefanadis, C; Toli, C, 2008
)
0.58
" The echocardiographic database, patient records, and the Social Security Death Index were reviewed for the timing and cause of death, severe adverse events, arrhythmias, and symptoms."( Safety of ultrasound contrast agents in stress echocardiography.
Gabriel, RS; Grimm, RA; Klein, AL; Menon, V; Sabik, EM; Smyth, YM; Thomas, JD, 2008
)
0.35
" Contrast use, hemodynamics, and adverse clinical and electrocardiographic events were evaluated until time of discharge from the laboratory."( Safety of contrast administration for endocardial enhancement during stress echocardiography compared with noncontrast stress.
Chang, SM; Kurrelmeyer, K; Nagueh, SF; Peterson, L; Quinones, MA; Rosendahl-Garcia, K; Shaikh, K; Zoghbi, WA, 2008
)
0.35
" The aim of this study was to compare various pharmacological stress tests alone or in combination with low intensity exercise as preparation for MPS in regard to incidence of adverse effects, quality of diagnostic image and the acquisition initial time."( [Study of efficacy and safety of pharmacological stress tests in nuclear cardiology].
Agbaba, N; Baskot, B; Gligić, B; Obradović, S; Orozović, V; Rafajlovski, S; Ristić-Angelkov, A, 2009
)
0.35
"Piloerection is a frequent side effect of dobutamine infusion, particularly in patients aged 50 or less; it usually precedes the increase in heart rate caused by dobutamine; therefore, it is an early and clear indication that the intravenous set is working properly."( Piloerection: a side effect of intravenous administration of dobutamine.
Vidal, I, 2009
)
0.86
" The subclinical cardiac toxicity could be evaluated by dobutamine stress echocardiography (DSE) with exploring effective and safe doses of dobutamine."( [The role of dobutamine stress echocardiography in early diagnosis of cardiac toxicity in long-term survivors of asymptomatic children treated with anthracycline].
Ilhan, M; Karadeniz, C; Kula, S; Oğuz, A; Oğuz, D; Olguntürk, R; Pinarli, FG; Tunaoğlu, FS; Yildirim, A, 2010
)
0.98
"The DSE is an effective and safe method to demonstrate the late anthracycline cardiotoxicity."( [The role of dobutamine stress echocardiography in early diagnosis of cardiac toxicity in long-term survivors of asymptomatic children treated with anthracycline].
Ilhan, M; Karadeniz, C; Kula, S; Oğuz, A; Oğuz, D; Olguntürk, R; Pinarli, FG; Tunaoğlu, FS; Yildirim, A, 2010
)
0.73
"Early injection of atropine during dobutamine stress echocardiography has been demonstrated in retrospective analyses to reduce the duration and dose of dobutamine infusion, while preserving a similar diagnostic accuracy with a lower incidence of adverse effects."( Early atropine is safer than conventional atropine administration in the elderly undergoing dobutamine stress echocardiography.
Abdel-Salam, Z; Nammas, W, 2010
)
0.86
"In elderly patients undergoing dobutamine stress echocardiography, adopting the early atropine protocol offers a shorter test duration and a lower dobutamine dose, with consequently fewer adverse effects."( Early atropine is safer than conventional atropine administration in the elderly undergoing dobutamine stress echocardiography.
Abdel-Salam, Z; Nammas, W, 2010
)
0.87
" An ideal inotropic drug should restore effective tissue perfusion by enhancing myocardial contractility without causing adverse effects."( Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
Campia, U; Gheorghiade, M; Nodari, S, 2010
)
0.36
"These data corroborate that induced hypertension may be a safe treatment option to prevent cerebral infarction in CVS, even in the presence of unsecured aneurysms."( Unsecured intracranial aneurysms and induced hypertension in cerebral vasospasm: is induced hypertension safe?
Beck, J; Berkefeld, J; Güresir, E; Platz, J; Raabe, A; Seifert, V; Vatter, H, 2011
)
0.37
"We conclude that stress CMR, with adenosine as the main stress agent, is well tolerated, safe and accurate in routine clinical practice."( Stress cardiovascular MR in routine clinical practice: referral patterns, accuracy, tolerance, safety and incidental findings.
Coulden, RA; Grundy, BJ; Khoo, JP; McCann, GP; Sonnex, EP; Steadman, CD, 2012
)
0.38
" The incidences of adverse reactions and events were similar between two groups."( [Comparison on efficacy and safety between domestic levosimendan versus dobutamine for patients with acute decompensated heart failure].
Bai, XJ; Huang, Y; Jiang, YN; Li, H; Liu, WX; Qing, EM; Qu, P; Sun, YX; Wei, BQ; Zhang, J; Zhang, L; Zhang, YH; Zhou, Q, 2012
)
0.61
"Exercise is safer than dobutamine stress echocardiography, complications and adverse effects with the use of dobutamine are usually minor and self-limiting."( Stress echocardiography: safety and tolerability.
Abdelali, S; Abir, S; Berrada, A; Chaara, A; Cherradi, R; Cherti, M; Doghmi, N; Elhajjaji, I; Ellouali, F; Fennich, N, 2013
)
0.7
" Adverse events were defined as significant arrhythmias (sinus arrest, Mobitz type II heart block, complete heart block, ventricular tachycardia, or ventricular fibrillation), hypotension requiring hospitalization, syncope or presyncope, myocardial infarction, and death."( The risk of adverse events associated with atropine administration during dobutamine stress echocardiography in cardiac transplant patients: a 28-year single-center experience.
Haythe, J; Schulze, PC; Shimbo, D; Wang Ji, J; Ye, S, 2013
)
0.62
" Therefore, patients should be appropriately monitored for these adverse events during and after DSE."( The risk of adverse events associated with atropine administration during dobutamine stress echocardiography in cardiac transplant patients: a 28-year single-center experience.
Haythe, J; Schulze, PC; Shimbo, D; Wang Ji, J; Ye, S, 2013
)
0.62
" There were no serious adverse effects."( Safety and feasibility of dobutamine stress cardiac magnetic resonance for cardiovascular assessment prior to renal transplantation.
Bellenger, NG; Chawner, RR; Gosling, OE; Hossain, E; Kannoly, S; Moore, J; Ripley, DP; Shore, AC, 2014
)
0.7
"Early injection of atropine during dobutamine stress echocardiography (DSE) has been demonstrated in retrospective analyses to reduce the duration and dose of dobutamine infusion, while preserving a similar diagnostic accuracy with a lower incidence of adverse effects."( Atropine first is safer than conventional atropine administration in older people undergoing dobutamine stress echocardiography.
Shehata, M, 2014
)
0.9
" Patients were monitored for adverse drug effects."( Atropine first is safer than conventional atropine administration in older people undergoing dobutamine stress echocardiography.
Shehata, M, 2014
)
0.62
"In older patients undergoing DSE, using atropine as a start drug, that is, adopting the ADSE protocol, is associated with shorter test duration, lower mean dobutamine infusion rate and consequently fewer adverse effects."( Atropine first is safer than conventional atropine administration in older people undergoing dobutamine stress echocardiography.
Shehata, M, 2014
)
0.82
"Performance of stress CMR is safe in a referral population."( Pharmacological stress cardiovascular magnetic resonance: feasibility and safety in a large multicentre prospective registry.
Estornell Erill, J; Garcia Gonzalez, P; Igual Muñoz, B; Lopez-Lereu, MP; Maceira Gonzalez, A; Monmeneu Menadas, JV, 2016
)
0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" In conclusion, prolonged AI and/or LS infusions in HF are safe and beneficial even in small infants, allowing stabilization and reasonable social and family life out of the hospital."( Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.
Apostolopoulou, SC; Kakava, F; Rammos, S; Tsoutsinos, A; Vagenakis, GA, 2018
)
0.48
" Changes in hemodynamic parameters from baseline and adverse events were also assessed."( Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.
Aberle, C; Altshuler, D; Lewis, TC; Papadopoulos, J; Piper, GL, 2019
)
0.76
" Modifying the hospital pharmacotherapy system to include standard solutions is safer and reduces the risks of adverse effects."( Standard concentration infusions of inotropic and vasoactive drugs in paediatric intensive care: a strategy for patient safety.
Barreto, HAG; Boergen-Lacerda, R; Sestren, B; Soares, LCDC, 2019
)
0.51
" We select literature according to prespecified inclusion and exclusion criteria and record data such as drug type, mortality, and adverse reactions."( Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S, 2020
)
0.56
" Milrinone was most effective at reducing mortality and had the lowest incidence of adverse reactions."( Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S, 2020
)
0.56
"This network meta-analysis demonstrated that milrinone was the most effective medication at reducing mortality and adverse events in patients suffering from cardiogenic shock."( Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S, 2020
)
0.56
" Other criteria for discontinuing the infusion were major adverse events: ventricular arrhythmia, persistent supraventricular arrhythmia, pulmonary edema, chest pain with significant ST-changes, or minor events: ST-changes, drop in systolic blood pressure >30 mmHg, mild chest pain, and/or dyspnea."( Safety and feasibility of dobutamine stress echocardiography in symptomatic high gradient aortic stenosis patients scheduled for transcatheter aortic valve implantation.
Aaberge, L; Beitnes, JO; Halvorsen, PS; Saevik, M, 2021
)
0.92
" No patient had major adverse event."( Safety and feasibility of dobutamine stress echocardiography in symptomatic high gradient aortic stenosis patients scheduled for transcatheter aortic valve implantation.
Aaberge, L; Beitnes, JO; Halvorsen, PS; Saevik, M, 2021
)
0.92
"Low-dose dobutamine stress test appeared safe and feasible patients with high gradient aortic stenosis, and showed LV flow reserve in a minority of them."( Safety and feasibility of dobutamine stress echocardiography in symptomatic high gradient aortic stenosis patients scheduled for transcatheter aortic valve implantation.
Aaberge, L; Beitnes, JO; Halvorsen, PS; Saevik, M, 2021
)
1.34
" The safety, adverse effects, and efficacy of DopSE were then assessed in 105 patients, 98 of whom had ALD."( Safety and feasibility of dopamine-atropine stress echocardiography.
Feigenbaum, H; Ghumman, W; Khemka, A; Mahenthiran, J; Rao, RA; Sawada, SG, 2021
)
0.62
" In 105 patients who underwent DopSE, none had adverse effects that required early stress termination."( Safety and feasibility of dopamine-atropine stress echocardiography.
Feigenbaum, H; Ghumman, W; Khemka, A; Mahenthiran, J; Rao, RA; Sawada, SG, 2021
)
0.62
"Dopamine-atropine stress echocardiography appears to be a safe stress modality and provides greater increases in RPP in patients with ALD compared to DSE."( Safety and feasibility of dopamine-atropine stress echocardiography.
Feigenbaum, H; Ghumman, W; Khemka, A; Mahenthiran, J; Rao, RA; Sawada, SG, 2021
)
0.62
" Adverse effects and resistance to loop diuretics received much attention while the contribution of a depressed cardiac output to diuretic resistance was downplayed."( Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure.
Le Jemtel, T; Rajapreyar, I; Samson, R; Stencel, J, 2022
)
0.72

Pharmacokinetics

Study provides data on the variability of the elimination half-life of dobutamine in the very preterm infant during transitional circulation. Traditional pharmacodynamic modeling revealed a wide range in responses to dobutamines. The pharmacokinetic parameters of landiolol in presence of do butamine showed a short half- life (3.5 hours)

ExcerptReferenceRelevance
" A first-order pharmacokinetic model was validated by lack of dependence of dose on clearance and an established graphical method."( Variability in dobutamine pharmacokinetics in unstable critically ill surgical patients.
Dasta, JF; Flancbaum, LJ; Klem, C; Reilley, TE, 1994
)
0.64
"Prospective, pharmacokinetic study using sequential, graded dosing of drug."( Dobutamine infusions in stable, critically ill children: pharmacokinetics and hemodynamic actions.
Berg, RA; Donnerstein, RL; Padbury, JF, 1993
)
1.73
"Pharmacokinetic and pharmacodynamic data on adrenergic agents in children have revealed wide ranges of plasma clearance rates and hemodynamic responses in patients with critical illnesses or myocardial dysfunction."( Dobutamine pharmacokinetics and pharmacodynamics in normal children and adolescents.
Berg, RA; Donnerstein, RL; Hutter, JJ; Klewer, SE; Padbury, JF, 1993
)
1.73
"Dobutamine has a half-life of 2 min and requires up to 10 min to achieve steady state."( Effects of prolonging peak dobutamine dose during stress echocardiography.
Foster, GP; Picard, MH; Rose, GA; Weissman, NJ, 1997
)
2.04
"To determine the pharmacodynamic parameters of dobutamine during dobutamine stress echocardiography (DSE) and to determine how beta-blocker withdrawal the evening before DSE affects responses to dobutamine during DSE."( Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of beta-blocker withdrawal: a report from the Women's Ischemic Syndrome Evaluation Study.
Humma, LM; Johnson, JA; Lewis, JF; McGorray, SP; Pepine, CJ; Richardson, HE, 2002
)
2.01
" Traditional pharmacodynamic modeling revealed a wide range in responses to dobutamine."( Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of beta-blocker withdrawal: a report from the Women's Ischemic Syndrome Evaluation Study.
Humma, LM; Johnson, JA; Lewis, JF; McGorray, SP; Pepine, CJ; Richardson, HE, 2002
)
1.99
" We present a structured literature review of pharmacokinetic and pharmacodynamic data for dobutamine in the pediatric population."( A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates.
Crook, D; Mahoney, L; Rabe, H; Rojas-Anaya, H; Shah, G, 2016
)
0.89
" Knowledge of the elimination half-life is essential to estimate the steady state when its efficacy/safety can be evaluated."( Pharmacokinetic study (phase I-II) of a new dobutamine formulation in preterm infants immediately after birth.
Bravo, MC; Cabañas, F; Fernández, R; Gleeson, C; Jullien, V; Koch, A; Ortego, PL; Pellicer, A; Rabe, H; Rojas-Anaya, H; Sánchez, L; Smith, A; Ybarra, M, 2021
)
0.88
"Analysis of pharmacokinetic data in ten preterm newborns treated with a new neonatal formulation of dobutamine (IMP) after screening for haemodynamic insufficiency within the first 72 h from birth."( Pharmacokinetic study (phase I-II) of a new dobutamine formulation in preterm infants immediately after birth.
Bravo, MC; Cabañas, F; Fernández, R; Gleeson, C; Jullien, V; Koch, A; Ortego, PL; Pellicer, A; Rabe, H; Rojas-Anaya, H; Sánchez, L; Smith, A; Ybarra, M, 2021
)
1.1
" This study provides data on the variability of the elimination half-life of dobutamine in the very preterm infant during transitional circulation."( Pharmacokinetic study (phase I-II) of a new dobutamine formulation in preterm infants immediately after birth.
Bravo, MC; Cabañas, F; Fernández, R; Gleeson, C; Jullien, V; Koch, A; Ortego, PL; Pellicer, A; Rabe, H; Rojas-Anaya, H; Sánchez, L; Smith, A; Ybarra, M, 2021
)
1.11
"To study the pharmacokinetic and -dynamic behavior of landiolol in the presence of dobutamine in healthy subjects of European ancestry."( Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.
Hodisch, J; Kadlecová, P; Krumpl, G; Trebs, M; Ulč, I, 2020
)
1.02
" The pharmacokinetic parameters of landiolol in presence of dobutamine showed a short half-life (3."( Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.
Hodisch, J; Kadlecová, P; Krumpl, G; Trebs, M; Ulč, I, 2020
)
1.04

Compound-Compound Interactions

Amrinone (AMR), a phosphodiesterase inhibitor, alone and in combination with dobutamine (DOB), on hemodynamics and O2 delivery were studied during porcine endotoxemia. The aim of this study is to compare the acute hemodynamic effects of inhaled nitroglycerine (iNTG), intravenous nitrog triglycerine (IV NTG) alone and their combination with intravenous dobutamines (IV DOB)

ExcerptReferenceRelevance
"The haemodynamic effects of the Ca-agonist BAY K 8644 alone and in combination with the selective beta-I-adrenoceptor agonist dobutamine were studied in the isolated rabbit heart."( Pharmacodynamics of BAY K 8644 alone and in combination with dobutamine in the isolated rabbit heart.
Pedersen, OL; Sørensen, EV, 1989
)
0.72
") in combination with dobutamine and dopamine."( [Successful use of amrinone in combination with dobutamine in the treatment of severe heart failure].
Firt, P; Málek, I; Vojtísková, J, 1989
)
0.85
") was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine."( Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine.
Glock, D; Goldberg, LI; Lass, NA, 1988
)
0.69
"Effects of amrinone (AMR), a phosphodiesterase inhibitor, alone and in combination with dobutamine (DOB), on hemodynamics and O2 delivery were studied during porcine endotoxemia."( Amrinone combined with dobutamine improves hemodynamics and oxygen delivery without down-regulation of cardiac beta-adrenergic receptor density in porcine endotoxemia.
Dodam, JR; Gengo, PJ; Hellyer, PW; Jones, JL, 1995
)
0.82
"Dobutamine stress combined with echocardiography or perfusion scintigraphy may be used to detect coronary artery disease."( Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both?
Baudhuin, T; D'Hondt, AM; Detry, JM; Marwick, T; Melin, J; Wijns, W; Willemart, B, 1993
)
2.08
" Left ventricular function, systemic arterial blood pressure, and heart rate (HR) responses to TM alone and in combination with propranolol(P) or dobutamine HCl(DOB) were evaluated."( Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs.
Main, BW; Means, JR; Rinkema, LE; Sarazan, RD; Smith, WC, 1996
)
0.7
"To compare the hemodynamic effects of dopamine with those of dobutamine when administered with milrinone in patients undergoing non-cardiac surgery."( Dopamine may preserve the myocardial oxygen balance better than dobutamine when administered with milrinone.
Karasawa, F; Okuda, T; Takamatsu, I, 2002
)
0.79
" Dopamine administered with milrinone significantly increased MAP and cardiac output (CO), whereas dobutamine significantly increased HR and CO, but decreased SVR."( Dopamine may preserve the myocardial oxygen balance better than dobutamine when administered with milrinone.
Karasawa, F; Okuda, T; Takamatsu, I, 2002
)
0.77
"Dopamine and dobutamine administered with milrinone induce different hemodynamic changes: dopamine increases MAP without affecting HR, whereas dobutamine increases HR."( Dopamine may preserve the myocardial oxygen balance better than dobutamine when administered with milrinone.
Karasawa, F; Okuda, T; Takamatsu, I, 2002
)
0.92
"To examine the effects of long-term intermittent dobutamine infusion, combined with oral amiodarone in patients with congestive heart failure (CHF) refractory to standard medical treatment."( Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study.
Anastasiou-Nana, MI; Kanakakis, J; Moon, T; Nanas, JN; Nanas, SN; Terrovitis, JV; Tsagalou, EP, 2004
)
0.89
"Long-term intermittent dobutamine infusion combined with amiodarone added to the conventional drugs improved the survival of patients with advanced CHF that was refractory to conventional treatment."( Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study.
Anastasiou-Nana, MI; Kanakakis, J; Moon, T; Nanas, JN; Nanas, SN; Terrovitis, JV; Tsagalou, EP, 2004
)
0.94
"This study was sought to compare the sensitivity, specificity and accuracy of (1) dual isotope simultaneous acquisition single-photon emission computed tomography (DISA SPECT) myocardial image with (99m)Tc-sestamibi/(18)F-fluorodeoxyglucose ((99m)Tc-MIBI/(18)FDG); (2) low dose dobutamine alone and combined with Isosorbide Dinitrate (ISDN: Isoket) stress two dimensional echocardiography (2DE) to predict regional movement recovery after revascularization (CRV) in patients with old myocardial infarction (OMI) and severe left ventricular dysfunction."( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction].
Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005
)
0.8
"9%) underwent low dose dobutamine 10 microg x kg(-1) x min(-1) (Dob10 microg) and ISDN (286 +/- 31 microg/min) combined with Dob5 microg (ISDN-Dob 5 microg) 2DE and DISA SPECT within one week."( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction].
Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005
)
0.93
" When ISDN combined with Dob5 microg, the sensitivity (91."( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction].
Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005
)
0.62
" Increasing evidence suggests the use of levosimendan in combination with dobutamine in patients with decompensated heart failure that is refractory to dobutamine alone."( The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu, Y, 2007
)
0.81
"The purpose of the present study was to provide evidence regarding the safety of real-time flash-contrast echocardiography combined with dobutamine-atropine stress echo (DASE)."( Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischaemia in 5250 studies.
Aggeli, C; Christoforatou, E; Giannopoulos, G; Marinos, G; Pitsavos, C; Roussakis, G; Stefanadis, C; Toli, C, 2008
)
0.78
" We examined whether intermittent inotropic agents combined with oral amiodarone to prevent the proarrhythmic effect of inotropic agents results in better outcomes."( Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C, 2009
)
0.35
"Intermittent intravenous inotropic agents combined with prophylactic oral amiodarone seem to improve the outcomes of patients with end-stage chronic heart failure."( Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C, 2009
)
0.35
" The aim of this study is to compare the acute hemodynamic effects of inhaled nitroglycerine (iNTG), intravenous nitroglycerine (IV NTG) alone and their combination with intravenous dobutamine (IV DOB) during the early postoperative period, in patients with PAH undergoing mitral valve or double valve replacement surgery."( Acute hemodynamic effects of inhaled nitroglycerine, intravenous nitroglycerine, and their combination with intravenous dobutamine in patients with secondary pulmonary hypertension.
Choudhury, M; Chowdhury, U; Kapoor, PM; Kiran, U; Mandal, B,
)
0.53
" Only iNTG produced selective pulmonary vasodilatation, while IV NTG and its combination with IV dobutamine had a significant concomitant systemic vasodilatory effect."( Acute hemodynamic effects of inhaled nitroglycerine, intravenous nitroglycerine, and their combination with intravenous dobutamine in patients with secondary pulmonary hypertension.
Choudhury, M; Chowdhury, U; Kapoor, PM; Kiran, U; Mandal, B,
)
0.56
"Using transthoracic three-dimensional (3D) echo regional volume analysis combined with low-dose dobutamine to investigate the effects on regional volume, mitral configuration and functional mitral regurgitation (FMR)."( The impact of segmental volumetric changes on functional mitral regurgitation: a study using three-dimensional regional time-volume analysis combined with low-dose dobutamine.
Chen, X; Hsiung, MC; Mu, Y, 2014
)
0.82
"To compare the effects of a lidocaine constant rate infusion (CRI) combined with 1% isoflurane versus those of 2% isoflurane alone on cardiovascular variables in anaesthetized horses, and to estimate the sample size required to detect a difference in recovery quality."( Comparison of the effects of an intravenous lidocaine infusion combined with 1% isoflurane versus 2% isoflurane alone on selected cardiovascular variables and recovery characteristics during equine general anaesthesia.
Cruz Benedetti, IC; Fourel, I; Le Bris, M; Mongellas, E; Nottrott, K; Portier, K, 2017
)
0.46
"A lidocaine CRI combined with FIIso 1% rather than FIIso 2% alone may improve cardiovascular variables in healthy anaesthetized horses."( Comparison of the effects of an intravenous lidocaine infusion combined with 1% isoflurane versus 2% isoflurane alone on selected cardiovascular variables and recovery characteristics during equine general anaesthesia.
Cruz Benedetti, IC; Fourel, I; Le Bris, M; Mongellas, E; Nottrott, K; Portier, K, 2017
)
0.46
"The present study was performed in order to investigate the safety and efficacy of different vasoactive drugs combined with enteral nutrition in terms of treating elderly patients with sepsis."( Comparison of norepinephrine, dopamine and dobutamine combined with enteral nutrition in the treatment of elderly patients harboring sepsis.
Cui, JK; Ding, SS; Liu, M; Shang, XK; Zhou, WJ, 2021
)
0.88
"To evaluate the clinical effect of corrected left ventricular ejection time (LVETc) combined with dobutamine on the intraoperative management of patients undergoing hepatectomy for hepatocellular carcinoma."( The impacts of corrected left ventricular ejection time combined with dobutamine on hepatocellular carcinoma patients.
Jian, Y; Shiqiang, S; Xiaochen, J; Yu, N; Zongjian, S, 2022
)
1.17

Bioavailability

ExcerptReferenceRelevance
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Dobutamine stress echocardiography was safely performed using supplemental atropine and an aggressive dosing protocol. The animals were randomized to receive an intravenous infusion of norepinephrine-dobutamines in combination or dopamine alone.

ExcerptRelevanceReference
" In atria incubated with phenoxybenzamine from guinea-pigs pretreated with reserpine only the dopamine dose-response curves were displaced to the right indicating a considerable indirect sympathomimetic component."( Analysis of the inotropic: chronotropic selectivity of dobutamine and dopamine in anaethetised dogs and guinea-pig isolated atria.
Broadley, KJ; Levy, GP; Lumley, P, 1977
)
0.5
" Nine patients were then treated, with a dosage of 8 microgram/kg/min."( [The value of dobutamine in cardiology].
Bardet, J; Baudet, M; Bourdarias, JP; Rigaud, M, 1978
)
0.62
" Propranolol (3 X 10(-8) and 10(-7) M) provoked a shift to the right of the dose-response curve for dobutamine."( Response of the atrial pacemaker to dobutamine.
Aramendía, P; Márquez, MT; Puntoni de Mikulić, LE, 1977
)
0.75
" Particularly with the primarily cardioselective beta-stimulating agent dobutamine a marked positive inotropic effect can be achieved in a range of dosage not significantly affecting heart rate and peripheral resistance."( [Catecholamines for treatment of severe heart failure (author's transl)].
Kübler, W; Mäurer, W; Tillmanns, H, 1979
)
0.49
" The specific therapy can then be effectively and safely delivered by a careful analysis of the dose-response relation as identified by hemodynamic monitoring."( Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
Armstrong, PW, 1979
)
0.26
" The dose-response data demonstrated that dobutamine (2."( Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.
Bush, CA; Heban, PT; Huss, P; Leier, CV; Lewis, RP, 1978
)
0.76
" The dosage of dobutamine started from 2 mug/kg/min and was increased stepwise to 4, 6, and 8 mug/kg/min."( Hemodynamic effects of dobutamine in patients following open heart surgery.
Sakamoto, T; Yamada, T, 1977
)
0.92
" At dosage levels yielding similar increases in cardiac index (12 patients), nitroprusside resulted in significantly lower arterial systolic and wedge pressures and did not increase heart rate suggesting advantages over dobutamine when reduction in myocardial oxygen requirement or pulmonary congestion is a major goal."( Comparative responses to dobutamine and nitroprusside in patients with chronic low output cardiac failure.
Berkowitz, C; Croke, RP; Gunnar, RM; Jacobs, WR; Loeb, HS; McKeever, L, 1977
)
0.75
" Dose-response curves were thus obtained for A-H and H-V intervals."( Effects of dobutamine on atrioventricular conduction.
Beregovich, J; Bianchi, C; Diaz, R; Gonzales, C, 1975
)
0.64
" Our findings were: (1) profound hypothermia (30 degrees C) causes significant depression of hemodynamic functions; (2) IV infusion of dopamine and dobutamine can be used safely and effectively for inotropic support during profound hypothermia, and the optimal dosage for improving cardiac output is 10-20 micrograms/kg/min; (3) no risk of inducing arrhythmia was noted with IV infusion of both inotropes up to a maximum dosage of 30 micrograms/kg/min, even though significant sinus tachycardia was consistently seen at 30 micrograms/kg/min."( Effects of hypothermia on hemodynamic responses to dopamine and dobutamine.
Chiu, RC; English, M; Hinchey, EJ; Oung, CM, 1992
)
0.72
" The dobutamine infusion dosage (5, 10, 15, and 20 micrograms/kg of body weight/min) was increased at 5-minute intervals."( Parasympathetic influence on the arrhythmogenicity of graded dobutamine infusions in halothane-anesthetized horses.
Hellyer, PW; Light, GS; Swanson, CR, 1992
)
1.04
"5 micrograms/kg/min steps every 15 minutes up to a maximum dosage of 10 micrograms/kg/min."( Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term effects and lack of tolerance.
Bleifeld, W; Erlemeier, HH; Kupper, W, 1992
)
0.59
" CVP and PCWP were depressed at both dosage levels."( [Effects of dobutamine and isoproterenol on systemic hemodynamics and myocardial metabolism in children after open heart surgery].
Anzai, T; Hamada, Y; Iijima, T; Ishikawa, S; Kodama, H; Obayashi, T; Otaki, A; Sakata, Y; Yanagisawa, H; Yoshida, I, 1992
)
0.66
" The multitissue bath was evaluated by determining the dose-response curves to dobutamine in isolated rabbit right ventricular papillary muscles."( A multitissue organ bath evaluated using new rabbit papillary muscle isolation methods.
Amsterdam, EA; Rendig, SV, 1992
)
0.51
" The therapeutic implications are dependent on the nature of the underlying cardiomyopathy and the fact that beta-adrenergic receptor desensitization is unlikely to be overcome by progressive dosage increases."( Outpatient dobutamine therapy: the rhyme and the riddle.
Araghi, A; Dietrich, KA; Dooley, F; Landau, SW; Mene, M; Sacher, HL; Sacher, ML, 1992
)
0.67
" Thirty minutes later, alinidine was administered as a bolus dosage of 1 mg/kg in five dogs; the other five dogs served as a control group."( Addition of alinidine, a specific bradycardic agent, to dobutamine in a canine model of endotoxic shock.
Moulart, D; Preiser, JC; Vincent, JL, 1992
)
0.53
" These findings demonstrate that dopamine acts on glucoregulation divergently, according to the dosage applied."( Comparative effects of dopamine and dobutamine on glucoregulation in a rat model.
Foldenauer, A; Keck, FS; Pfeiffer, EF; Wolf, CF; Zeller, G, 1991
)
0.56
" Dose-response curves were obtained for the inotropic, chronotropic and pressor responses to cumulative infusions of noradrenaline (n = 6) and dobutamine (n = 6)."( The effects of neuropeptide Y on myocardial contractility and coronary blood flow.
Awad, SJ; Einstein, R; Potter, EK; Richardson, DP, 1991
)
0.48
" In this study we examined the dose-response effects of dobutamine in 8 patients with chronic heart failure."( Dobutamine stress testing in chronic heart failure--dose-response effects assessed by echo-Doppler.
Guy, S; Silke, B, 1991
)
1.97
" Treatment was associated with mild transient hypokalaemia in 7 patients, and hyponatraemia and renal impairment in 1, for whom metolazone dosage had to be reduced."( Metolazone in treatment of severe refractory congestive cardiac failure.
Arter, WJ; Field, MJ; Kiyingi, A; Lawrence, JR; Pawsey, CC; Yiannikas, J, 1990
)
0.28
"The hemodynamic effects of dopexamine hydrochloride and dobutamine were compared during dose-response infusions of dopexamine (1."( Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and effects on hemodynamics and urine output.
Baumann, G; Felix, SB; Filcek, SA, 1990
)
0.78
" Redetermination of the dose-response function for clenbuterol, following 2 weeks of repeated daily administration, showed that clenbuterol no longer affected DRL behavior at doses up to 3 mg/kg."( Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol.
O'Donnell, JM, 1990
)
0.28
"Four intravenous doses of piroximone, an imidazolone derivative, were administered to 12 patients with congestive heart failure to produce a four-point dose-response curve."( Piroximone, dobutamine and nitroprusside: comparative effects on haemodynamics in patients with congestive heart failure.
Baumann, G; Cremer, G; Joder-Ohlenbusch, AM; Ningel, K; Vieweg, J, 1991
)
0.66
" On the other hand, systemic vascular resistance (SVR) and left atrial pressure (LAP) were decreased at both dosage levels."( [Effects of dopamine and dobutamine on systemic hemodynamics and myocardial metabolism in children after open heart surgery].
Anzai, T; Iijima, T; Ishikawa, S; Kodama, H; Obayashi, T; Otaki, A; Sakata, Y; Yanagisawa, H; Yoshida, I, 1991
)
0.58
" With the dosage used, enoximone appeared to be at least as effective as conventional therapy in acute pulmonary oedema."( Acute pulmonary oedema: preliminary results of a randomized trial of the intravenous phosphodiesterase inhibitor, enoximone, vs conventional therapy.
Chassing, A; Flammang, D; Tarral, A; Waynberger, M, 1990
)
0.28
" After routine bicycle ergometer exercise RNV, dobutamine infusion was started at 5 micrograms/kg/min and the dosage was increased by 5 micrograms/kg/min every 4 minutes to a total of 15 micrograms/kg/min."( Radionuclide assessment of left ventricular function during dobutamine infusion in patients with coronary artery disease: comparison with ergometer exercise.
Aoki, T; Futagami, Y; Konishi, T; Koyama, T; Nakano, T; Watanabe, K; Yada, T; Yamamuro, M, 1990
)
0.78
"The comparative haemodynamic dose-response effects of intravenous (i."( Comparative haemodynamic dose-response effects of dobutamine and amrinone in left ventricular failure complicating acute myocardial infarction.
Midtbo, KA; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1987
)
0.53
" We conclude that milrinone exerts significant regional vasodilating effects in a conscious rat model, being most prominent in the coronary and cerebral circulations at a dosage that does not alter central hemodynamics."( Central and regional vascular hemodynamics following intravenous milrinone in the conscious rat: comparison with dobutamine.
Drexler, H; Faude, F; Höing, S; Just, H; Wollschläger, H, 1987
)
0.48
" Total peripheral resistance was calculated over a stable period of the last 5 min of each dosing and before administration of dobutamine."( [Dose-dependent vasodilator effect of dobutamine in calves with a constant cardiac output artificial heart].
Binhas, M; Deleuze, P; Kawasaki, K; Loisance, D; Videcoq, M, 1989
)
0.75
" An increase in stroke volume was observed at low dosage of dobutamine in both groups."( Haemodynamic alterations during ischaemia induced by dobutamine stress testing.
Albert, A; Berthe, C; Carlier, J; Kulbertus, HE; Piérard, LA, 1989
)
0.77
" Twice daily doses (50 mg/kg body wt) of the non-selective beta-adrenergic agonist, isoproterenol, for six days, increased Ca-ATPase specific activity of parotid gland by 17 per cent but that of submandibular gland was the same as controls; with dobutamine, the same dosage caused a 53 per cent decrease in submandibular activity and a 31 per cent decrease in parotid."( Ca-ATPase activity in salivary glands of rats treated with reserpine, isoproterenol, terbutaline or dobutamine.
Cheung, H; Schneyer, CA, 1987
)
0.67
" Dose-response curves were determined for either isoproterenol or dobutamine 30 min after treatment with hexamethonium (20mg/kg)."( Role of alpha-adrenergic receptors in the intrinsic inotropic selectivity of dobutamine in anesthetized dogs.
Gorczynski, RJ; Shaffer, JE, 1985
)
0.74
", increase in cell size but not cell number was observed; moreover, the same dosage effected an increase in DNA of parotid but not submandibular gland."( Growth of rat salivary glands after terbutaline or dobutamine.
Schneyer, CA, 1986
)
0.52
" The relatively limited cardiac output response and downward trend at the highest dosage of dopamine occurred with a reduction in heart rate and an increase in systemic vascular resistance."( Augmentation of cardiac output with intravenous catecholamines in unanesthetized hypoxemic newborn lambs.
Dreyer, WJ; Fisher, DJ; O'Laughlin, MP; Smith, EO, 1987
)
0.27
" Each patient was then switched to the other agent at approximately the same dose rate, titrating the dosage to the same cardiac output, and repeat measurements were made at 20 minutes when again stable."( Comparison of dopamine and dobutamine in patients requiring postoperative circulatory support.
Cohn, LH; Collins, JJ; DiSesa, VJ; Gold, JP; Shemin, RJ, 1986
)
0.57
" Each drug was titrated to optimal dosage (dobutamine, 12."( Combined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dobutamine and nitroprusside.
Cornyn, J; Loge, D; Massie, BM; Podolin, RA; Topic, N, 1987
)
0.75
" Both drugs produced dose-related increases in cardiac output and venous admixture; however, with dopamine the dose-response curve reached a plateau at doses greater than 40 micrograms/kg."( Cardiorespiratory and metabolic effects of dopamine and dobutamine infusions in dogs.
Abdul-Rasool, IH; Chamberlain, JH; Swan, PC; Ward, DS, 1987
)
0.52
" The dose-response curve of left ventricular dP/dt and performance during titration of dobutamine with and without the addition of intravenous amrinone was evaluated in seven patients."( Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure.
Gage, J; LeJemtel, TH; Lucido, D; Rutman, H, 1986
)
0.82
" The acute denervation of spinal anesthesia altered venous and arterial dose-response relationships of both drugs."( Effect of total spinal anesthesia on arterial and venous responses to dopamine and dobutamine.
Austin, JC; Berrizbeitia, LD; Butterworth, JF; Cohn, LH; Dance, GR; Howard, G; Johnson, MD, 1987
)
0.5
" A thorough understanding of the applied pharmacology, dosage recommendations, toxicity, and practical considerations must be attained before these drugs can be used effectively."( Pharmacology and pharmacokinetics of drugs used to treat cardiac disease in horses.
McGuirk, SM; Muir, WW, 1985
)
0.27
" Left ventricular dp/dt and cardiac output were increased in horses given dobutamine at dosage of 3 micrograms/kg/min and in those given either of the drugs at dosages of 5 and 10 micrograms/kg/min."( Hemodynamic responses in halothane-anesthetized horses given infusions of dopamine or dobutamine.
Bednarski, RM; Hubbell, JA; Muir, WW; Skarda, RT; Swanson, CR, 1985
)
0.72
" Nitroglycerin applied in a low dosage with exclusive venodilator effect was added for treatment of pulmonary edema and left ventricular failure."( [Hemorrhagic pulmonary edema and cardiac failure following isolated head injury. Treatment with dobutamine and nitroglycerin (author's transl)].
Jüngst, BK; Schranz, D; Stopfkuchen, H, 1981
)
0.48
" Using three beta-adrenoceptor agonists: terbutaline (beta 2), dobutamine (beta 1), and isoprenaline and monitoring atenolol's antagonism of the agonist effects on heart rate, airway elastance and soleus muscle tension, parallel shifts in dose-response curves for each agonist were observed on each parameter."( The determination of beta-adrenoceptor antagonist cardioselectivity "in vivo": atenolol in anaesthetized cats.
Kiyingi, KS; Temple, DM, 1983
)
0.51
" Three days post-AMI the dose-response curve for isoproterenol of right ventricular dP/dtmax was significantly depressed, while the inotropic effect of impromidine was not impaired."( Apparent superiority of H2-receptor stimulation and simultaneous beta-blockade over conventional treatment with beta-sympathomimetic drugs in post-acute myocardial infarction: cardiac effects of impromidine--a new specific H2-receptor agonist-in the survi
Baumann, G; Blömer, H; Felix, SB; Heidecke, CD; Loher, U; Ludwig, L; Riess, G, 1984
)
0.27
" Dose-response curves to the racemate were always situated between the stereoisomers, approximately 2-fold to the right of (+)-dobutamine."( Alpha and beta adrenergic effects of the stereoisomers of dobutamine.
Murphy, PJ; Pollock, GD; Ruffolo, RR; Spradlin, TA; Waddell, JE, 1981
)
0.71
" When the dosage of dobutamine was increased to 200 micrograms ."( Effects of adrenergic agonists on electrolyte transport in perfused salivary duct of rat.
Jirakulsomchok, D; Schneyer, CA, 1984
)
0.59
" When guidelines for patient selection and dosing are adhered to, ventricular dysfunction and cardiac decompensation secondary to atherosclerotic occlusive coronary artery disease can be improved without adversely affecting the myocardial oxygen supply and demand balance."( Drugs five years later. Dobutamine.
Leier, CV; Unverferth, DV, 1983
)
0.57
" We conclude that epinephrine, dopamine, and dobutamine are capable of producing cardiac arrhythmias in vagotomized and nonvagotomized thiamylal-halothane anesthetized dogs and that bilateral vagotomy decreases the dosage of epinephrine, dopamine, and dobutamine required to produce cardiac arrhythmias."( Arrhythmogenicity of dopamine, dobutamine, and epinephrine in thiamylal-halothane anesthetized dogs.
Bednarski, RM; Muir, WW, 1983
)
0.81
" The effect of sulmazol was greater than the effect of an increased dosage of dobutamine in five patients in whom this was studied."( Hemodynamic effects of sulmazol (ARL-115 BS), a new vasodilator and positive inotropic agent, in patients with cardiogenic shock.
Hugenholtz, PG; Muskens, G; Simoons, ML, 1983
)
0.49
" Dosage and side effect information, in particular, cannot be reliably extrapolated from data derived from studies in adults."( The position of the pharmaceutical industry in the development of drugs for pediatric use.
Christensen, CN, 1980
)
0.26
" The addition of enoximone to dobutamine resulted in an upward and leftward shift of the dobutamine dose-response curve for both cAMP production and contractile response."( Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart.
Bristow, MR; Gilbert, EM; Hershberger, RE; Movsesian, MA; Wiechmann, RJ, 1995
)
0.58
" Slope of log dose-response for heart rate and QS2i was similar with dobutamine and with isoprenaline, corresponding to stimulation of the same type of beta-adrenergic receptors (beta 1-subtype)."( Evaluation of cardiac beta 1-adrenergic sensitivity with dobutamine in healthy volunteers.
Chalon, S; Diquet, B; Lechat, P; Pousset, F; Thomaré, P, 1995
)
0.77
" Isolated atrial strips showed a right shift of their dose-response curve to isoprenaline in the presence of the highly selective beta 2-AR antagonist ICI 118,551 at concentrations above 1 x 10(-8) mol/L."( The effects of sympathomimetics on the cardiovascular system of sheep.
Allen, R; Alley, MR; Baxter, S; Burgess, C; Crane, J; Dallimore, JA; Davie, PS; Kealey, AS; Lapwood, KR; Pack, RJ, 1994
)
0.29
") or placebo was added from D0 for the next 28 days, while the dobutamine dosage was progressively decreased after D4 and eventually stopped at D7."( Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure.
Arnal, JF; Bourdarias, JP; Chikli, F; Delorme, G; Dubourg, O; Dumas, C; Jondeau, G; Kamoun, L, 1994
)
0.53
"Dobutamine stress echocardiography was safely performed using supplemental atropine and an aggressive dosing protocol."( Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients.
Feigenbaum, H; Foltz, J; Kovacs, R; Mertes, H; Ryan, T; Sawada, SG; Segar, DS, 1993
)
1.97
"4) mm Hg at a median dobutamine dosage of 20 micrograms/kg/min and from 25."( Response to dobutamine and dopamine in the hypotensive very preterm infant.
Lefèvre, M; Maingueneau, C; Mouzard, A; Rozé, JC; Tohier, C, 1993
)
0.98
" These results suggest a 50% reduction in morphine dosage in children requiring inotropic support following cardiac surgery."( Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support.
Barker, G; Bohn, D; Dagan, O; Klein, J; Koren, G, 1993
)
0.29
"Prospective, controlled dose-response comparison of dopamine and dobutamine."( Cardiovascular effects of dopamine and dobutamine in conscious pigs with chronic heart failure.
van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1993
)
0.79
"Prospective, pharmacokinetic study using sequential, graded dosing of drug."( Dobutamine infusions in stable, critically ill children: pharmacokinetics and hemodynamic actions.
Berg, RA; Donnerstein, RL; Padbury, JF, 1993
)
1.73
" Hemodynamic responses were evaluated by paired t-test and by computerized evaluation of individual dose-response curves."( Dobutamine infusions in stable, critically ill children: pharmacokinetics and hemodynamic actions.
Berg, RA; Donnerstein, RL; Padbury, JF, 1993
)
1.73
" Hemodynamic responses to dobutamine generally follow a predicted log-linear dose-response model."( Dobutamine infusions in stable, critically ill children: pharmacokinetics and hemodynamic actions.
Berg, RA; Donnerstein, RL; Padbury, JF, 1993
)
2.03
" Dobutamine clearance was linear over the dosage range evaluated."( Dobutamine pharmacokinetics and pharmacodynamics in normal children and adolescents.
Berg, RA; Donnerstein, RL; Hutter, JJ; Klewer, SE; Padbury, JF, 1993
)
2.64
"The usual protocol for dobutamine stress echocardiography is a sensible one, because the haemodynamic effect occurs already at low dosage and can then be increased significantly with further dosage steps."( [Normal values for dobutamine stress echocardiography].
Erbel, R; Meyer, J; Mohr-Kahaly, S; Nixdorff, U; Wagner, S; Weitzel, P, 1995
)
0.93
" There was a wide interday variability in the measured catecholamine dosage in patients receiving the same dose for 3 days or more."( Difference between the measured and ordered dose of catecholamine infusions.
Allen, EM; Dean, JM; Olsen, AF; Van Boerum, DH, 1995
)
0.29
" Beta-adrenergic blockade with propranolol shifted the agonist's dose-response curves for heart rate and contractility to the right; however, low doses of dobutamine exhibited a negative chronotropic effect and increased the total peripheral vascular resistance."( A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent.
Abou-Mohamed, G; Caldwell, RW; Myers, T; Nagarajan, R, 1996
)
0.49
" Echocardiography was analysed in the 4 standard views which were digitised allowing calculation of a regional wall motion score under basal conditions and at peak dosage in 16 left ventricular segments."( [Value of dobutamine echocardiography in the detection of coronary disease in heart transplant patient. Groupe de Recherche VACOMED].
Cribier, A; Derumeaux, G; Letac, B; Mouton-Schleifer, D; Redonnet, M; Soyer, R, 1996
)
0.7
"0 mg/kg) were administered to complete a dose-response curve."( Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs.
Main, BW; Means, JR; Rinkema, LE; Sarazan, RD; Smith, WC, 1996
)
0.5
" The dosage of dopamine ranged from 4 to 28 micrograms/kg per minute and the dosage of dobutamine varied from 4 to 24 micrograms/kg per minute."( Pulse oximetry in newborn infants with birth weights of 620 to 4285 grams receiving dopamine and dobutamine.
Durand, M; Johnson, C; Maarek, JM; McEvoy, C; Sardesai, S,
)
0.57
" Dobutamine challenge at a dosage ranging from 27."( Cardiac performance in conscious healthy dogs during dobutamine infusion.
Balligand, M; Clercx, C; D'Orio, V; Henroteaux, M; McEntee, K; Peeters, D; Pypendop, B, 1996
)
1.45
" L-NMMA coinfusion inhibited responses (area under the dose-response curve) to isoproterenol (0."( Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm.
Chowienczyk, PJ; Dawes, M; Ritter, JM, 1997
)
0.3
" Despite supplemental atropine, an aggressive dosing protocol and the inclusion of patients with a myocardial scar or history of heart failure, adverse effects were rare and often did not require any specific therapy."( Dobutamine stress echocardiography in the elderly Asian patients.
Chai, P; Choo, MH; Ling, LH; Ng, WL; Yeo, TC; Yeoh, JK, 1997
)
1.74
" Dose-response curves for the effects of isoprenaline (non selective beta-agonist), salbutamol (beta2-agonist), dobutamine (beta1-agonist) on ICa were obtained in the absence and presence of various concentrations of ICI 118551 (beta2-antagonist), metoprolol (beta1-antagonist) and xamoterol (partial beta1-agonist) to derive EC50 (i."( Pharmacological characterization of the receptors involved in the beta-adrenoceptor-mediated stimulation of the L-type Ca2+ current in frog ventricular myocytes.
Fischmeister, R; Jurevicius, J; Skeberdis, VA, 1997
)
0.51
"These isovolumic relaxation variables shortened with the increment of dobutamine dosage and were markedly prolonged when ischemia developed."( Modification of left ventricular isovolumic relaxation time during dobutamine echocardiography as a diagnostic method for ischemic heart disease.
Cherng, WJ; Hung, MJ; Wang, CH, 1997
)
0.77
" The median final dosage of dobutamine was 13."( The effect of dobutamine on distal colon ischaemia in the pig.
Bergqvist, D; Björck, M; Haglund, U, 1998
)
0.95
"Ppa and Pc' were measured at baseline and after an increase in Q induced either by exercise or by an infusion of dobutamine, at a dosage up to 8 microg/kg body weight per min, in 11 patients with primary pulmonary hypertension."( Partitioning of pulmonary vascular resistance in primary pulmonary hypertension.
Brimioulle, S; Kafi, SA; Mélot, C; Naeije, R; Vachiéry, JL, 1998
)
0.51
"From the selected studies, information was obtained regarding patient population, dosing regimen, duration of study, and effects on splanchnic blood flow (SBF), splanchnic oxygenation, and pHi."( Effects of vasoactive drugs on gastric intramucosal pH.
Créteur, J; DeBacker, D; Silva, E; Vincent, JL, 1998
)
0.3
" At the peak of its dose-response curve, saterinone induced an increase in cardiac index (+102%), stroke volume (+97%), and heart rate (+6%), paralleled by a decrease in pulmonary capillary wedge pressure (-46%), right atrial pressure (-51%), pulmonary arterial pressure (systolic -32%, diastolic -45%, mean -38%), systemic blood pressure (systolic -3%, diastolic -13%, mean -9%), systemic vascular resistance (-54%), and pulmonary vascular resistance (-58%)."( Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
Baumann, G; Iven, H; Kieback, AG; Stolzenburg, K, 1998
)
0.68
"5 microg/kg/min, with further improvement as the dosage increased."( Effects of dopamine, dobutamine, dopexamine, phenylephrine, and saline solution on intramuscular blood flow and other cardiopulmonary variables in halothane-anesthetized ponies.
Alibhai, HI; Clarke, KW; Lee, YH; Song, D, 1998
)
0.62
" Starting dosage of dobutamine was 2 microg/kg/min, which was raised gradually up to 12 microg/kg/min, or until the appearance of complaints or symptoms."( Arrhythmic effects of intermittent dobutamine therapy in chronic heart disease failure. The Working Group of Cardiology of the Academic Committee of Veszprém, Hungary.
Junger, E; Liziczai, I; Nagy, L; Tarján, J, 1998
)
0.9
" Doppler measurements were recorded at baseline and at each stage of dobutamine infusion, whereas aortic diameter was measured at baseline and at peak dosage by use of two-dimensional echocardiography."( Doppler echocardiographic study of left and right ventricular function during dobutamine stress testing in conscious healthy dogs.
Amory, H; Clercx, C; Dardenne, JJ; Henroteaux, M; McEntee, K; Michaux, C; Soyeur, D, 1999
)
0.77
" The clinical signs of tissue hypoperfusion improved, and optimal hemodynamic parameters were achieved at a mean +/- SD dobutamine dosage of 17 +/- 7 microg/kg/min."( Dobutamine in severe scorpion envenomation: effects on standard hemodynamics, right ventricular performance, and tissue oxygenation.
Abroug, F; Besbes-Ouanes, L; Boukef, R; Boussarsar, M; Elatrous, S; Marghli, S; Nouira, S, 1999
)
1.95
" The dose-response curve for HR was shifted leftward in heart transplant patients."( Safety profile and hemodynamic responses to beta-adrenergic stimulation by dobutamine in heart transplant patients.
Akosah, KO; Denlinger, B; Mohanty, PK, 1999
)
0.53
" After baseline measurement for systemic, splanchnic, and femoral blood flow (by dye dilution); oxygen consumption; gastric mucosal pressure of carbon dioxide (Pco2); total and splanchnic glucose production (by stable isotope tracer dilution); and regional lactate and amino acid balance, patients received either dobutamine, at a dosage (6 microg x kg(-1)min(-1)) sufficient to increase cardiac index by at least 25%, or placebo."( Effect of dobutamine on splanchnic carbohydrate metabolism and amino acid balance after cardiac surgery.
Ensinger, H; Georgieff, M; Rantala, A; Takala, J; Vogt, J, 1999
)
0.88
" A dobutamine perfusion was given at increasing dosage up to 50 micrograms/kg/min, in combination with intravenous atropine if needed to obtain a heart rate close to the theoretical maximum."( [Diagnostic value of electrocardiography using dobutamine in coronary artery disease].
Arsenescu, I; Extramiana, F; Fournier, C; Mokaddem, J; Witchitz, S, 1999
)
1.18
"The aim of this study was to evaluate retrospectively the importance of a Bayesian pharmacokinetic approach for predicting vancomycin concentrations to individualize its dosing regimen in 18 critically ill patients admitted to intensive care units following cardiothoracic surgery."( High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.
Baraldo, M; Furlanut, M; Pea, F; Porreca, L, 2000
)
0.31
" Infants were randomly allocated to two groups and received a 5% albumin infusion at a dosage of 20 mL/kg, in 30 min."( Assessment of therapy for arterial hypotension in critically ill preterm infants.
Ruelas-Orozco, G; Vargas-Origel, A, 2000
)
0.31
" Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg."( Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.
Ahlberg, AW; Heller, GV; Katten, D; Murthy, DR; Salloum, A; White, CM, 2000
)
0.79
" Dobutamine is capable of improving both contractile function and cellular energetics in the hypoperfused RV myocardium, but dosage should be carefully selected."( Dobutamine enhances both contractile function and energy reserves in hypoperfused canine right ventricle.
Bian, X; Downey, HF; Fu, M; Mallet, RT; Yi, KD, 2000
)
2.66
"Clonidine, dobutamine, and dopexamine at high dosage suppress the gastric mucosal vasodilator response to acid back diffusion, which is an important defense mechanism."( Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach.
Holzer, P; Painsipp, E, 2001
)
0.96
"DO2 was increased by dobutamine infusion, starting with an initial dosage of 5 microg x kg x min, increased to a maximum of 10 microg x kg x min."( Different dosages of dobutamine in septic shock patients: determining oxygen consumption with a metabolic monitor integrated in a ventilator.
Sanft, C; Schaefer, JH; Schaffartzik, W; Spies, C, 2000
)
0.94
" Within the first 10 hrs after baseline measurements, the dosage was increased until no further increase in the left ventricular stroke work index occurred."( Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients.
Kaulfuss, M; Kern, H; Kox, WJ; Martin, M; Schröder, T; Spies, CD, 2001
)
0.61
" The intracavitary pressure gradient at peak dosage of dobutamine for both patients was 121 mm Hg and 100 mm Hg, and was reproducibly confirmed by cardiac catheterization."( Hypotension and functional left ventricular obstruction during dobutamine stress echocardiography--two case reports.
Kohno, M; Mizushige, K; Ueda, T; Watanabe, K; Yukiiri, K, 2001
)
0.8
"dobutamine was administered for 12 h/day for 20+/-23 days at a dosage of 7+/-3 microg/kg/min to 43 patients."( Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome.
Capomolla, S; Caporotondi, A; Cobelli, F; Febo, O; Gnemmi, M; Guazzotti, G; La Rovere, MT; Maestri, R; Mortara, A; Opasich, C; Pinna, GD; Vona, M, 2001
)
2.08
" If 4 or more segments were estimated to be viable initially, the left ventricular ejection fraction improved to a value comparable to that obtained at a dosage of 20 micrograms/Kg/min of dobutamine."( [Prediction of improvement of left ventricular systolic function by dobutamine echocardiography after recent myocardial infarction].
Bonfils, L; Brasselet, C; Deschildre, A; Elaerts, J; Jamet, B; Laury, P; Lozé, O; Metz, D; Nazeyrollas, P; Tassan-Mangina, S, 2001
)
0.74
"07) and BB dosage (OR=0."( Dobutamine echocardiography in idiopathic dilated cardiomyopathy: clinical and prognostic implications.
Di Lenarda, A; Gregori, D; Perkan, A; Pinamonti, B; Sinagra, G, 2002
)
1.76
"001), but because the slope of both dose-response curves was reduced by 48% after L-NNA ( P<0."( Divergent effects of NO synthase inhibition on systemic and myocardial O2 delivery and consumption during dobutamine infusion in sheep.
Penny, DJ; Smolich, JJ, 2002
)
0.53
"01), a trend toward a higher ED50 (dobutamine dosage rate causing half the maximum heart-rate response; median 16."( Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of beta-blocker withdrawal: a report from the Women's Ischemic Syndrome Evaluation Study.
Humma, LM; Johnson, JA; Lewis, JF; McGorray, SP; Pepine, CJ; Richardson, HE, 2002
)
2.03
" A sensitivity analysis on dosage of drug and duration of survival was performed."( Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Apajasalo, M; Cleland, JG; Kobelt, G; Takala, A; Zethraeus, N, 2003
)
0.56
"Assessment of ventricular contractile reserve by dobutamine stress echocardiography (DSE) may be a powerful tool for detection of subclinical ventricular dysfunction, however, the hemodynamic dose-response relationship during DSE in children has not been established."( Moderate-dose dobutamine maximizes left ventricular contractile response during dobutamine stress echocardiography in children.
Khoury, P; Kimball, TR; Michelfelder, EC; Witt, SA, 2003
)
0.93
" Dose-response curves for shortening fraction, VCFc, WS, and contractility (the difference between actual and predicted VCFc for measured WS) were obtained."( Moderate-dose dobutamine maximizes left ventricular contractile response during dobutamine stress echocardiography in children.
Khoury, P; Kimball, TR; Michelfelder, EC; Witt, SA, 2003
)
0.68
"Use of isometric handgrip exercise with DASE decreases time to target heart rate, recovery time, overall study time, and mean dosage of dobutamine and atropine."( Isometric handgrip exercise during dobutamine-atropine stress echocardiography increases heart rate acceleration and decreases study duration and dobutamine and atropine dosage.
Moldenhauer, S; Sherrid, MV; Yao, SS, 2003
)
0.8
" The animals were randomized to either receive an intravenous infusion of norepinephrine-dobutamine in combination or dopamine alone, and the dosage was titrated to obtain a mean arterial pressure (MAP)> 90."( [Comparison of effect of norepinephrine-dobutamine and that of dopamine alone on splanchnic perfusion in sheep with septic shock].
Li, SQ; Qiu, HB; Tan, Y; Yang, Y; Zhou, SX, 2003
)
0.81
" Each group received dobutamine (5 microg x kg(-1) x min(-1)), and the dosage of norepinephrine was adjusted to achieve a mean arterial pressure between 70 and 80 mmHg."( Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock.
Coluzzi, F; Conti, G; De Gaetano, A; Morelli, A; Orecchioni, A; Pelaia, P; Pietropaoli, P; Rocco, M; Vernaglione, E, 2004
)
0.64
" These drug doses maximized survival duration in dose-response studies."( Adenosine A1 antagonism attenuates beta-adrenergic-resistant sudden hypoxic cardiac insufficiency.
Dalsey, WC; de Garavilla, L; Gao, E; Kaplan, JL; Victain, MS, 2005
)
0.33
" Once issues relating to optimal dosing and long-term effects of poloxamer 188 in humans have been resolved, chemical-based membrane sealants could represent a new therapeutic approach for preventing or reversing the progression of cardiomyopathy and heart failure in muscular dystrophy."( Dystrophic heart failure blocked by membrane sealant poloxamer.
Day, SM; Favre, EG; Metzger, JM; Michele, DE; Townsend, D; Yasuda, S, 2005
)
0.33
"During Dob 2DE, side effects rates increased by dosage, the drug even induced ischemia at a dosage of 10 microg."( [Pharmacological stress echocardiography for diagnosing of viable myocardium in severe left ventricular dysfunction].
Chen, JL; Hu, FH; Wang, YW; Yang, WX; Yang, YJ; You, SJ, 2005
)
0.33
" Dobutamine was continuously infused at a dosage of 3 microg kg(-1) min(-1)."( Levosimendan improves postresuscitation outcomes in a rat model of CPR.
Cammarata, G; Cao, L; Huang, L; Sun, S; Tang, W; Weil, MH, 2005
)
1.24
" The beta1-adrenoceptor agonist, dobutamine, and the alpha1-adrenoceptor agonist, phenylephrine, induced learning, and both exhibited an inverted U-curve dose-response relationship to odor preference learning."( Beta1-adrenoceptor or alpha1-adrenoceptor activation initiates early odor preference learning in rat pups: support for the mitral cell/cAMP model of odor preference learning.
Darby-King, A; Harley, CW; McCann, J; McLean, JH,
)
0.41
" Dobutamine stress dose-dependently increased cardiac function, which, however, was significantly smaller with a right shift of the dose-response curve in apoE-KO mice compared with WT controls."( Reduced cardiac functional reserve in apolipoprotein E knockout mice.
Martin-McNulty, B; Sullivan, ME; Vergona, R; Vincelette, J; Wang, YX, 2006
)
1.24
" All parameters increased at both dosage rates of dobutamine and decreased significantly when dobutamine administration ceased."( Effects of two different dosages of dobutamine on pulmonary artery wedge pressure, systemic arterial blood pressure and heart rate in anaesthetized horses.
Bubeck, K; Deegen, E; Gehlen, H; Ohnesorge, B; Stadler, P; Weichler, A, 2006
)
0.86
" Lower dosage of dobutamine increased heart rate, +dP/dtmax and -dP/dtmax only in STZ-diabetic rats, while the higher dosage promoted greater, but similar, responses in the three groups."( Myocardial performance in conscious streptozotocin diabetic rats.
Borges, GR; de Oliveira, M; Fazan, R; Salgado, HC, 2006
)
0.67
" Agonist dose-response curves to incremental drug infusions were acquired in 11 anesthetised rabbits using pressure-volume loops and preload recruitable stroke work indicated contractility."( The cardiovascular effects of adrenaline, dobutamine and milrinone in rabbits using pressure-volume loops and guinea pig isolated atrial tissue.
Angus, JA; Rohrlach, R; Royse, AG; Royse, CF; Wright, CE, 2007
)
0.6
" More data are needed regarding patient selection and the optimum regimen and dosing of levosimendan before this treatment modality become the first line therapy of acutely decompensated chronic heart failure patients."( Classical inotropes and new cardiac enhancers.
Farmakis, D; Nieminen, M; Parissis, JT, 2007
)
0.34
" A randomized controlled study was designed to examine the dose-response effect of dobutamine (5-20 microg x kg(-1) x min(-1)) on systemic and regional circulations and oxygen metabolism in a neonatal swine model of hypoxia/reoxygenation."( The hemodynamic effects of dobutamine during reoxygenation after hypoxia: a dose-response study in newborn pigs.
Abozaid, S; Al-Salam, Z; Bigam, D; Cheung, PY; Johnson, S, 2007
)
0.86
" The mean administered dosage ofdobutamine was 4 microg/kg/ min (range: 2-10)."( [Dobutamine therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in severe heart failure].
Brügemann, J; de Jonge-Weber, AT; Rienstra, M; van den Broek, SA; van Veldhuisen, DJ; Zijlstra, F, 2007
)
1.53
" Left ventricular hypokinesia was partially corrected by dobutamine, added to a reduced dosage of norepinephrine, or by epinephrine."( Actual incidence of global left ventricular hypokinesia in adult septic shock.
Belliard, G; Caille, V; Charron, C; Jardin, F; Page, B; Vieillard-Baron, A, 2008
)
0.59
" Our results showed that individuals with homozygous or heterozygous C393 had an increased cardiovascular agonistic response to dobutamine, and the increases from baseline in LVFS at the 3 dosage levels of dobutamine were 19."( Effect of 393T>C polymorphism of GNAS1 gene on dobutamine response in Chinese healthy subjects.
Chen, BL; Fan, L; Guo, D; Han, CT; Liu, ZQ; Mao, YM; Wang, SY; Yang, LJ; Zhou, HH, 2009
)
0.82
"This study in swine assessed BIS stability in response to decreases and increases in cardiac output under two propofol/remifentanil dosage combinations, both producing the same depth of surgical anaesthesia."( BIS response to tamponade and dobutamine in swine varies with hypnotic/opiate ratio.
Beydon, L; Cailleux, A; Chazot, T; Desfontis, JC; Dussaussoy, C; Ferec, S; Fischler, M; Ganster, F; Gautier, F; Gogny, M; Liu, N; Petres, J,
)
0.42
" These data suggest that step-up increase of dobutamine dosage is not always effective in raising CI in patients suffering from post-SAH vasospasm, but rather may cause some adverse effects associated with increased myocardial oxygen consumption as evidenced by high-dose infusion."( [Application of the FloTrac arterial pressure-based continuous cardiac output monitor to dobutamine-induced hyperdynamic therapy for cerebral vasospasm after subarachnoid hemorrhage].
Ishikawa, T; Mutoh, T; Yasui, N, 2009
)
0.83
" The authors also performed in vivo comparisons including pressure drift, dose-response studies to IV isoproterenol, maximum adrenergic stimulation with IV dobutamine, and simultaneous placement of both micro-manometer pressure sensors in the same intact murine hearts."( Validation of a new micro-manometer pressure sensor for cardiovascular measurements in mice.
Barton, A; Chisholm, GB; Escobedo, D; Feldman, MD; Jones, DL; Larson, E; Porterfield, J; Trevino, RJ,
)
0.33
"The current weight-based protocol of dobutamine dosing for DST results in similar increases in HR and blood pressure for patients of widely varying BMI."( Is the standard weight-based dosing of dobutamine for stress testing appropriate for patients of widely varying body mass index?
Barnes, ME; Bernheim, AM; Kittipovanonth, M; Pellikka, PA; Scott, CG; Shub, C, 2011
)
0.91
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Cardiopulmonary bypass (CPB) time, cross-clamp time, cardiac index, cumulative postoperative dosage of dobutamine, intensive care stay, postoperative hospital stay were not statistically different."( Effect of limb ischemic preconditioning on myocardial injury in patients undergoing mitral valve replacement surgery. -A randomized controlled trial-.
Ding, D; Dong, N; Gui, P; Purusram, G; Wu, J; Wu, Q; Yao, S, 2011
)
0.58
" The availability of drug and dosing information for prescribing was stated to be insufficient by 40% of participants, while 88% would appreciate clinical practice guidelines."( Treatment for paediatric low cardiac output syndrome: results from the European EuLoCOS-Paed survey.
Läer, S; Vogt, W, 2011
)
0.37
"To establish the test-retest reliability and the normal dose-response relationship of echocardiographic measures of Left Ventricular (LV) contractile function to low dose dobutamine stress in healthy individuals."( Are measures of left ventricular systolic performance during low dose dobutamine stress echocardiograms repeatable over time?
Elmayergi, NH; Goodman, JM; Lee, LS; Sasson, Z, 2013
)
0.82
" Stress end points were symptoms, >20 mmHg drop in systolic blood pressure, arrhythmia, or maximum dobutamine dosage of 40 μg/kg/min."( Patterns of cardiac dysfunction coinciding with exertional breathlessness in hypertrophic cardiomyopathy.
Chung, R; Duncan, A; Henein, MY; Li, W; Lindqvist, P; Maras, D; Mörner, S; Thorp, C, 2013
)
0.61
"The purpose of the study was to compare the effect of limited echocardiography (LE)-guided therapy to standard management on 28-day mortality, intravenous fluid prescription, and inotropic dosing following early resuscitation for shock."( Limited echocardiography-guided therapy in subacute shock is associated with change in management and improved outcomes.
Boyd, JH; Kanji, HD; MacRedmond, R; McCallum, J; Moss, R; Sirounis, D, 2014
)
0.4
" Our aim was to compare acute dose-response hemodynamic effects of inodilators dobutamine (DOB), milrinone (MIL), and levosimendan (LEV) in chronic experimental PH."( Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension.
Alaa, M; Leite, S; Leite-Moreira, AF; Lopes, L; Lourenço, AP; Oliveira-Pinto, J; Tavares-Silva, M, 2017
)
0.93
"Experimental, dose-response study."( Dose-dependent effects of isoflurane and dobutamine on cardiovascular function in dogs with experimental mitral regurgitation.
Goya, S; Hirao, D; Shimada, K; Tanaka, R; Wada, T, 2018
)
0.75
" The present study suggests that intravenous constant rate infusion and subcutaneous repeated administration of dexmedetomidine at indicated dosage can be useful in balanced anaesthesia without any systemic or local adverse effects; moreover, in healthy horses undergoing general anaesthesia, repeated subcutaneous dexmedetomidine administration may be a suitable alternative if constant rate infusion is not feasible."( Use of dexmedetomidine repeated subcutaneous administration for balanced anaesthesia in horses.
Amari, M; Brioschi, FA; Cagnardi, P; De Zani, D; Di Cesare, F; Di Giancamillo, M; Rabbogliatti, V; Ravasio, G; Zani, DD, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
cardiotonic drugA drug that has a strengthening effect on the heart or that can increase cardiac output.
sympathomimetic agentA drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
beta-adrenergic agonistAn agent that selectively binds to and activates beta-adrenergic receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
secondary amineA compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups.
catecholamine4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Dobutamine Action Pathway478

Protein Targets (63)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dopamine D1 receptorHomo sapiens (human)Potency3.26430.00521.30228.1995AID624455
glp-1 receptor, partialHomo sapiens (human)Potency5.80480.01846.806014.1254AID624148
thioredoxin reductaseRattus norvegicus (Norway rat)Potency14.12540.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
Fumarate hydrataseHomo sapiens (human)Potency2.23870.00308.794948.0869AID1347053
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
GLS proteinHomo sapiens (human)Potency5.79250.35487.935539.8107AID624146; AID624170
TDP1 proteinHomo sapiens (human)Potency20.78590.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency9.43920.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency29.05220.000221.22318,912.5098AID743035; AID743042; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency31.67040.000657.913322,387.1992AID1259377; AID1259378
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.23020.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency26.62350.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.73860.000229.305416,493.5996AID743078; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency13.80290.00108.379861.1304AID1645840
polyproteinZika virusPotency2.23870.00308.794948.0869AID1347053
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.83250.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency5.35380.023723.228263.5986AID743223
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency23.28090.016525.307841.3999AID602332
aryl hydrocarbon receptorHomo sapiens (human)Potency26.60320.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency33.49150.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency23.91450.143427.612159.8106AID1159516
Histone H2A.xCricetulus griseus (Chinese hamster)Potency50.15620.039147.5451146.8240AID1224845; AID1224896
D(1A) dopamine receptorHomo sapiens (human)Potency0.32640.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
gemininHomo sapiens (human)Potency7.46600.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency28.18380.009610.525035.4813AID1479145
Ataxin-2Homo sapiens (human)Potency35.48130.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)4.17000.21005.553710.0000AID1442001
Carbonic anhydrase 12Homo sapiens (human)Ki4.35000.00021.10439.9000AID501912
Bile salt export pumpHomo sapiens (human)IC50 (µMol)550.00000.11007.190310.0000AID1443986; AID1449628
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)5.55100.00000.536910.0000AID625184
Carbonic anhydrase 1Homo sapiens (human)Ki1.92000.00001.372610.0000AID501903
Carbonic anhydrase 2Homo sapiens (human)Ki0.48000.00000.72369.9200AID501904
Tyrosine-protein kinase LckHomo sapiens (human)IC50 (µMol)5.51900.00021.317310.0000AID625187
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)3.97500.00021.67898.6800AID625185
Carbonic anhydrase 3Homo sapiens (human)Ki7.40000.00022.010210.0000AID501905
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)1.51700.00020.93267.2000AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki1.04300.00000.66359.5499AID625205
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.38300.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.38000.00322.28879.3160AID625207
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)1.94400.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki1.12300.00011.33919.9840AID625204
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)0.59900.11003.26419.0330AID625146
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)2.96600.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki1.35400.00020.725710.0000AID625202
Carbonic anhydrase 4Homo sapiens (human)Ki8.98000.00021.97209.9200AID501906
Carbonic anhydrase 6Homo sapiens (human)Ki9.47000.00011.47109.9200AID501909
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.38300.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.38000.00031.465610.0000AID625207
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.11400.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.05600.00000.360910.0000AID625200
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)1.89500.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki1.00600.00000.70488.1930AID625222
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki0.73000.00001.27259.9000AID501907
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)4.98500.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki1.69300.00000.602010.0000AID625254
Carbonic anhydrase 7Homo sapiens (human)Ki4.30000.00021.37379.9000AID501910
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)0.15500.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.12300.00021.11158.0280AID625256
Carbonic anhydrase 9Homo sapiens (human)Ki9.82000.00010.78749.9000AID502077
Carbonic anhydrase 13Homo sapiens (human)Ki9.53000.00031.23099.8000AID501913
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)2.51800.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki1.05800.00000.490110.0000AID625223
Carbonic anhydrase 15Mus musculus (house mouse)Ki0.39000.00091.884610.0000AID501915
Carbonic anhydrase 14Homo sapiens (human)Ki12.02000.00021.50999.9000AID501914
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki0.89000.00001.34129.9700AID501908
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
mu-type opioid receptor isoform MOR-1Homo sapiens (human)EC50 (µMol)92.47000.13203.30049.5690AID720642
5-hydroxytryptamine receptor 2AMus musculus (house mouse)EC50 (µMol)76.08300.00381.36218.3930AID720643
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km28.40002.10005.39008.6000AID1769498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (471)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
intracellular zinc ion homeostasisTyrosine-protein kinase LckHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase LckHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
hemopoiesisTyrosine-protein kinase LckHomo sapiens (human)
platelet activationTyrosine-protein kinase LckHomo sapiens (human)
T cell differentiationTyrosine-protein kinase LckHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase LckHomo sapiens (human)
Fc-gamma receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell activationTyrosine-protein kinase LckHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LckHomo sapiens (human)
release of sequestered calcium ion into cytosolTyrosine-protein kinase LckHomo sapiens (human)
regulation of lymphocyte activationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of leukocyte cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
innate immune responseTyrosine-protein kinase LckHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 13Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (138)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
protein serine/threonine phosphatase activityTyrosine-protein kinase LckHomo sapiens (human)
protein bindingTyrosine-protein kinase LckHomo sapiens (human)
ATP bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase LckHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase LckHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD4 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD8 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
identical protein bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase LckHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
ATPase bindingTyrosine-protein kinase LckHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 13Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 13Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (99)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
pericentriolar materialTyrosine-protein kinase LckHomo sapiens (human)
immunological synapseTyrosine-protein kinase LckHomo sapiens (human)
cytosolTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase LckHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
myelin sheathCarbonic anhydrase 13Homo sapiens (human)
intracellular membrane-bounded organelleCarbonic anhydrase 13Homo sapiens (human)
cytoplasmCarbonic anhydrase 13Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (190)

Assay IDTitleYearJournalArticle
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1452484Positive inotropic activity in Sprague-Dawley rat heart assessed as ejection fraction at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 67.16 to 85.81%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60580Inotropic potency expressed as 100 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID76920Compound was tested for relative intrinsic activity in guinea pig isolated atrium right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID501905Inhibition of human carbonic anhydrase 3 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID58658Ionotropic selectivity expressed as change in heart rate for 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID1452517Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT max at 4 ug/kg/min (Rvb = 4985 to 5214 mmHg/s)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452508Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as heart rate at 8 ug/kg/min (Rvb = 260 to 322 bpm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1442001Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID1452479Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end systole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.07 to 2.46 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452477Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end systole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.07 to 2.46 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID57843Cardioselectivity expressed as change in blood pressure for 100% increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1452487Positive inotropic activity in Sprague-Dawley rat heart assessed as fractional shortening at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 38.60 to 55.81%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452519Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT min at 4 ug/kg/min (Rvb = -5462 to -4898 mmHg/s)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452485Positive inotropic activity in Sprague-Dawley rat heart assessed as ejection fraction at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 67.16 to 85.81%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452498Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT max at 8 ug/kg/min (Rvb = 4162 to 5214 mmHg/s)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452469Positive inotropic activity in Sprague-Dawley rat heart assessed as heart rate at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 281 to 347 bpm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1452478Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end systole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.07 to 2.46 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1847827Toxicity in Sprague-Dawley rat assessed as hemodynamic reponse by measuring increase in heart rate at 0.001 to 0.1 mg/kg/min, iv infusion administered for 15 mins by PV-loop based analysis2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Identification of a Hydroxypyrimidinone Compound (
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID502077Inhibition of human carbonic anhydrase 9 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1452493Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-diastolic pressure at 8 ug/kg/min (Rvb = 7.68 to 9.83 mmHg)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID501906Inhibition of human carbonic anhydrase 4 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1636402Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 0.3 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1452474Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end diastole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 5.66 to 7.80 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID57846Cardioselectivity expressed as change in blood pressure for 50% increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1124818Activation of FXR (unknown origin) at 10 uM2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Some non-conventional biomolecular targets for diamidines. A short survey.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID501903Inhibition of human carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1452486Positive inotropic activity in Sprague-Dawley rat heart assessed as fractional shortening at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 38.60 to 55.81%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID501909Inhibition of human carbonic anhydrase 6 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1636461Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 3.4 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1452476Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end diastole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 5.66 to 7.80 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452470Positive inotropic activity in Sprague-Dawley rat heart assessed as heart rate at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 281 to 347 bpm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID501913Inhibition of human carbonic anhydrase 13 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1136412Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity study of beta-adrenergic agents using the SIMCA method of pattern recognition.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID73727Effective concentration for increasing potency rate in guinea pig isolated right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID501914Inhibition of human carbonic anhydrase 14 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1452461Positive inotropic activity in Sprague-Dawley rat heart assessed as fractional shortening at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 38.60 to 55.81%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID501904Inhibition of human carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID501908Inhibition of human carbonic anhydrase 5b after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID76919Compound was tested for or relative intrinsic activity in guinea pig isolated atrium left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID73905Positive inotropic activity in spontaneously beating guinea pig atria1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Cardiovascular effects of new water-soluble derivatives of forskolin.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1452503Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as dPdT min at 8 ug/kg/min (Rvb = -5462 to -4611 mmHg/s)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452472Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end systole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.50 to 4.78 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1546919Vasorelaxant activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions by measuring maximum relaxation magnitude relative to control2020Journal of natural products, 01-24, Volume: 83, Issue:1
Schwarzinicines A-G, 1,4-Diarylbutanoid-Phenethylamine Conjugates from the Leaves of
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID501907Inhibition of human carbonic anhydrase 5a after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID501912Inhibition of human carbonic anhydrase 12 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1452468Positive inotropic activity in Sprague-Dawley rat heart assessed as heart rate at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 281 to 347 bpm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452513Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-systolic pressure at 4 ug/kg/min (Rvb = 94.65 to 97.85 mmHg)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452482Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end diastole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 0.88 to 1.54 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID73725Effective concentration for increasing potency force in guinea pig isolated left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1135200Positive inotropic activity in cat heart papillary muscle assessed as increase in contractile force at 0.8 ug/mL measured for 5 mins (Rvb = 1080 mg)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Trichloroacetamidines, a new class of positive inotropic agents.
AID1452475Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end diastole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 5.66 to 7.80 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60584Inotropic potency expressed as 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1546918Vasorelaxant activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions2020Journal of natural products, 01-24, Volume: 83, Issue:1
Schwarzinicines A-G, 1,4-Diarylbutanoid-Phenethylamine Conjugates from the Leaves of
AID1452515Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-diastolic pressure at 4 ug/kg/min (Rvb = 7.68 to 9.83 mmHg)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID501915Inhibition of mouse carbonic anhydrase 15 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1452521Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as heart rate at 4 ug/kg/min (Rvb = 260 to 322 bpm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1136413Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes relative to isoproterenol1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity study of beta-adrenergic agents using the SIMCA method of pattern recognition.
AID1452481Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end diastole at 8 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 0.88 to 1.54 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1452473Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end systole at 16 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.50 to 4.78 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1452471Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular internal diameter end systole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 2.50 to 4.78 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1452488Effect on hemodynamic parameters in Sprague-Dawley rat heart assessed as end-systolic pressure at 8 ug/kg/min (Rvb = 87.48 to 97.85 mmHg)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1636512Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 2.8 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1452483Positive inotropic activity in Sprague-Dawley rat heart assessed as ejection fraction at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 67.16 to 85.81%)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1452480Positive inotropic activity in Sprague-Dawley rat heart assessed as left ventricular posterior wall thickness end diastole at 4 ug/kg/min for 3 mins by echocardiographic analysis (Rvb = 0.88 to 1.54 mm)2017European journal of medicinal chemistry, Jul-07, Volume: 134Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID501910Inhibition of human carbonic anhydrase 7 after 15 mins by stopped flow CO2 hydration method2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID683699Antimalarial activity against liver stages of Plasmodium yoelii yoelii2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID58655Ionotropic selectivity expressed as change in heart rate for 100 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1999Molecular pharmacology, Nov, Volume: 56, Issue:5
Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)2004Molecular pharmacology, May, Volume: 65, Issue:5
Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the beta2 adrenergic receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,007)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990846 (14.08)18.7374
1990's2087 (34.74)18.2507
2000's1934 (32.20)29.6817
2010's915 (15.23)24.3611
2020's225 (3.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.44 (24.57)
Research Supply Index8.88 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index153.94 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (83.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials818 (12.87%)5.53%
Reviews582 (9.16%)6.00%
Case Studies404 (6.36%)4.05%
Observational28 (0.44%)0.25%
Other4,525 (71.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (85)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Dobutamine on the Cardiac Conduction System: Site-Specific Dose [NCT04249258]Early Phase 137 participants (Actual)Interventional2020-01-14Completed
The Effects of Dobutamine on Postoperative Systolic Deformation and Diastolic Function in Patients With Hypertrophic Cardiomyopathy Operated for Aortic Valve Stenosis [NCT01375335]Phase 410 participants (Anticipated)Interventional2011-06-30Suspended(stopped due to Insufficient patient eligible for recruitment)
Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs. [NCT03621618]30 participants (Anticipated)Interventional2019-03-31Recruiting
NeoAdapt 3: An Observational Study Investigating Novel Biomarkers in the Evaluation and Treatment of Neonatal Circulatory Insufficiency in Infants Suffering From Hypoxic Ischemic Encephalopathy. [NCT02051894]18 participants (Actual)Observational2014-09-30Completed
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction [NCT01354613]14 participants (Actual)Interventional2011-04-30Completed
Use of Transtoracic Ecocargiogram With Calculation of Left Ventricular Volume Index in the Initial Adjustment of Initial Dose of Dobutamine in Patients With Heart Failure and Cardiogenic Shock [NCT03727282]30 participants (Anticipated)Interventional2019-01-02Not yet recruiting
Valutazione Ecocardiografica Della Riserva Contrattile Del Ventricolo Destro Dopo Carico Volemico Acuto Mediante Sollevamento Passivo Delle Gambe e Durante Infusione di Dobutamina in Pazienti Affetti da Scompenso Cardiaco a Frazione d'Eiezione Ridotta (HF [NCT05797584]60 participants (Anticipated)Interventional2019-03-20Recruiting
Liberal Versus Restrictive Dobutamine in Cardiac Surgery (DOBUTACS): a Prospective Randomized Non-inferiority Clinical Trial [NCT02361801]Phase 3160 participants (Actual)Interventional2015-02-28Completed
A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems [NCT03098680]Phase 118 participants (Actual)Interventional2017-04-24Terminated(stopped due to Unable to recruit in time before end of PhD studentship)
Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure [NCT02133105]Phase 333 participants (Actual)Interventional2014-04-30Completed
Intraoperative Stress Test With Dobutamine and Speckle Tracking to Decrease Postoperative Mortality [NCT03365726]2,000 participants (Anticipated)Interventional2016-01-19Recruiting
Evaluation of Costs and Consequences of Alternative Strategies of Intraoperative Fluid and Pharmacological Optimization. A Randomized Clinical Trial [NCT01141894]150 participants (Actual)Interventional2010-03-31Terminated(stopped due to slow recruitment)
Investigation of the Use of Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC [NCT00338455]Phase 216 participants (Actual)Interventional2006-09-30Terminated(stopped due to DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment)
Low-dose Dobutamine Infusion and Single-dose Tocilizumab in Acute Myocardial Infarction Patients With High Risk of Cardiogenic Shock Development - a 2x2 Multifactorial, Double-blinded, Randomized, Placebo Controlled Trial [NCT05350592]Phase 2100 participants (Anticipated)Interventional2022-03-07Recruiting
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion: a Randomized Controlled Multi-center Trial [NCT04166331]Phase 3270 participants (Anticipated)Interventional2020-09-20Recruiting
Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock : a Randomised, Opened, Cross-over Study. Heart SHOCK-NORDOB Study [NCT03340779]Phase 340 participants (Anticipated)Interventional2018-01-15Not yet recruiting
Effects of Intraoperative, Goal-directed Crystalloid vs. Colloid Fluid Resuscitation on Microcirculation in Free Flap Reconstruction of Intraoral Tumours. [NCT03288051]30 participants (Actual)Interventional2014-04-28Completed
Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients [NCT03207165]Phase 4192 participants (Actual)Interventional2017-08-30Completed
The Analysis of Data Collected During Angiography and Dobutamine Stress Contrast Echocardiograms in the Pre-Evaluation of Kidney and Pancreas Transplant Patients [NCT00580437]150 participants (Actual)Interventional2003-04-30Completed
Low Flow Low Gradient Aortic Stenosis Relevance of the (re)Search for a Contractile Reserve [NCT02727504]86 participants (Actual)Observational2016-05-11Completed
Myocardial Perfusion and Contractile Reserve in End-stage Renal Disease: A Prospective Study Combining Myocardial Perfusion Scintigraphy and Dobutamine Stress Echocardiography [NCT04172064]377 participants (Actual)Observational [Patient Registry]2010-01-31Completed
Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial. [NCT03289728]1,756 participants (Anticipated)Interventional2018-04-04Recruiting
Prospective Analysis and Comparison of Conventional Stress Echocardiograms and Real-Time Myocardial Contrast Stress Echocardiogram; for Bristol-Myers Squibb Medical Imaging: The Definity RT-P During DSE Database [NCT00575549]0 participants Expanded AccessNo longer available
The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure [NCT00953303]Phase 2/Phase 3102 participants (Actual)Interventional2009-01-31Completed
Comparison of Dobutamine and Regadenoson Stress CMR [NCT00763035]Early Phase 114 participants (Actual)Interventional2009-01-31Terminated(stopped due to Potential participants with COPD/asthma unwilling to participate.)
[NCT02559141]80 participants (Actual)Interventional2014-03-31Completed
Comparison of Dobutamine Versus Milrinone for Renal Recovery in Patients With Cardiorenal Syndrome-A Prospective Cohort Study in Patients With Acute Decompensated Heart Failure [NCT02644057]Phase 20 participants (Actual)Interventional2016-03-31Withdrawn(stopped due to Could not enroll patients)
[NCT01042873]Phase 4100 participants (Anticipated)Interventional2010-01-31Recruiting
Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study) [NCT02767024]Phase 40 participants (Actual)Interventional2018-05-01Withdrawn(stopped due to No patients enrolled)
Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Patients Undergoing Major Abdominal Surgery [NCT00549419]Phase 460 participants (Actual)Interventional2007-10-31Completed
Evaluation of Right Ventricular Contractility Reserve Function During Dobutamine Stress in Patients Following Surgical Repair of Tetralogy of Fallot [NCT00557934]16 participants (Actual)Interventional2007-10-31Completed
A Randomized Trial Comparing Coronary CT Angiography and Stress Echocardiography for Evaluation of Low-to-Intermediate Risk Emergency Department Chest Pain Patients [NCT01384448]400 participants (Actual)Interventional2011-08-31Completed
Dobutamine Versus Milrinone in Management of Critically Ill Low Cardiac Output Pediatric Patients at Cairo University Children's Hospital [NCT05999487]40 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test [NCT05025644]Phase 460 participants (Anticipated)Interventional2023-03-31Not yet recruiting
Supernormal Oxygen Delivery for Patients With Severe Burns:A Randomized Controlled Trial [NCT05241912]Early Phase 1100 participants (Anticipated)Interventional2022-02-28Not yet recruiting
Does Early Initiation of Renal Replacement Therapy Have an Impact on 7-day Fluid Balance in Critically Ill Patients With Acute Kidney Injury With Positive Furosemide Stress Test?: a Multicenter Randomized Controlled Trial [NCT02730117]118 participants (Actual)Interventional2016-03-31Completed
Can Dobutamine and Goal-Directed Fluid Therapy Improve Tissue Oxygenation in Deep Inferior Epigastric Perforator (DIEP) Flap Breast Reconstruction Surgery? Randomized Controlled Trial [NCT04020172]Phase 1/Phase 240 participants (Anticipated)Interventional2019-07-12Recruiting
Levosimendan and Inhaled Nitric Oxide for Resuscitating the Microcirculation in Septic Shock. A Randomized Controlled Trial [NCT00800306]Phase 240 participants (Actual)Interventional2007-11-30Completed
Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography [NCT02327455]0 participants (Actual)Interventional2023-07-31Withdrawn(stopped due to Study was never started.)
Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic [NCT01930734]Phase 460 participants (Anticipated)Interventional2013-10-31Not yet recruiting
The Effects of Levosimendan on Renal Function in Patients With Low Ejection Fraction Undergoing Mitral Valve Surgery. [NCT01969071]Phase 4140 participants (Actual)Interventional2009-07-31Completed
Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients. [NCT01271153]20 participants (Actual)Interventional2010-08-31Completed
Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy [NCT04893655]Phase 458 participants (Actual)Interventional2021-09-14Completed
[NCT02012946]Phase 440 participants (Anticipated)Interventional2013-12-31Not yet recruiting
[NCT02019810]Phase 220 participants (Anticipated)Interventional2014-10-31Recruiting
Cardiac Imaging Under Exercise Stress Test for Early Assessment of Right Ventricular Function in Patients With Tetralogy of Fallot and Pulmonary Regurgitation [NCT00564993]Phase 353 participants (Actual)Interventional2007-11-30Terminated
The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients [NCT04604886]40 participants (Anticipated)Interventional2020-09-30Recruiting
The Impact of Dobutamine and Nitrite on Myocardial Supply and Demand in Heart Failure [NCT02888561]45 participants (Anticipated)Observational2016-10-31Not yet recruiting
Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization [NCT00074724]319 participants (Actual)Interventional2003-05-31Completed
An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study [NCT01418118]Phase 425 participants (Actual)Interventional2008-10-31Completed
Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock: A Randomised Controlled Study [NCT02963454]50 participants (Anticipated)Interventional2011-01-31Recruiting
Effect of Dobutamine as Compared to Dopamine on Cerebral Oxygenation, Mean Arterial Pressure and Cerebral Hemodynamics in Term and Preterm Neonates With Arterial Hypotension [NCT01427686]Phase 420 participants (Anticipated)Interventional2011-06-30Active, not recruiting
Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study [NCT00093301]Phase 2/Phase 340 participants Interventional2004-10-31Recruiting
The Consistency of Cardiac Output Measurements by Different Methods in VA-ECMO Patients [NCT04102072]20 participants (Anticipated)Interventional2019-08-23Recruiting
Utility of Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aortic Stenosis Undergoing TAVI [NCT05196815]10 participants (Anticipated)Interventional2022-07-01Recruiting
Early Diagnosis of Diastolic Dysfunction and Reliability of Dobutamine Stress Echo (DSE) in Detecting Stress Diastolic Dysfunction [NCT00998205]16 participants (Actual)Interventional2008-06-30Completed
[NCT00484133]Phase 480 participants (Anticipated)Interventional2007-06-30Recruiting
Randomised Double Blind Clinical Trial of Dobutamine Versus Placebo for Low Superior Vena Cava Flow Treatment in Low Birth Weight Infants: Systematic Assessment of Cerebral and Systemic Hemodynamics Effects [NCT01605279]Phase 2127 participants (Actual)Interventional2010-09-30Completed
Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation. [NCT05953142]Phase 2120 participants (Anticipated)Interventional2023-08-01Not yet recruiting
Effects of Adding Ivabradine in Patients With Cardiogenic Shock Requiring Inotropic Support [NCT05594342]Phase 3200 participants (Anticipated)Interventional2022-07-01Recruiting
Allograft Vasculopathy After Heart Transplantation : Diagnostic Interest of Dobutamine Stress Echocardiography and Brain Natriuretic Peptide Coupling [NCT00384540]53 participants (Actual)Interventional2006-09-30Completed
Évaluation de l'Echographie de Stress Par Comparaison à la Coronarographie Comme Outil Non Invasif de détection de la resténose Intra endoprothèse du Tronc Commun [NCT01620320]0 participants (Actual)Observational2010-07-31Withdrawn(stopped due to No Funding)
Cardiac Dysfunction in Cirrhosis: Cirrhotic Cardiomyopathy Evaluated by Dobutamin MRI. [NCT00250315]0 participants Observational2005-11-30Completed
Cardiovascular Hyporeactivity and Fatiguing Illness in Gulf War Veterans [NCT00100412]0 participants Interventional1999-10-31Completed
Postoperative Prolonged Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation: a Retrospective Analysis of Risk Factors and Impact on Outcomes [NCT05702333]150 participants (Actual)Observational2017-02-01Completed
Prospective, Multicenter, Randomized, Double-Blind Study Comparing Safety and Efficacy of Norepinephrine Plus Dobutamine Versus Epinephrine Alone in Septic Shock. [NCT00148278]Phase 2/Phase 3330 participants (Actual)Interventional1999-10-31Completed
Hemodynamics and Extravascular Lung Water in Acute Lung Injury: A Prospective Randomized Controlled Multicentered Trial of Goal Directed Treatment of EVLW Versus Standard Management for the Treatment of Acute Lung Injury [NCT00624650]Phase 233 participants (Actual)Interventional2008-02-29Completed
Prediction of Left Ventricular Remodelling in Patients Treated by Angioplasty in the Acute of Phase of a First Myocardial Infarction by Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT [NCT00487812]50 participants (Anticipated)Interventional2004-12-31Completed
[NCT00000554]Phase 30 participants Interventional2001-05-31Completed
The Consistency of Cardiac Output Measured by Electrical Cardiometry and Pulmonary Artery Catheter in Cardiac Surgery Patients With Pulmonary Arterial Hypertension or Right Heart Dysfunction [NCT05587400]199 participants (Anticipated)Interventional2022-07-27Recruiting
Allopurinol and Cardiac Function Pilot Study in Idiopathic Dilated Cardiomyopathy [NCT00281255]Phase 1/Phase 20 participants (Actual)Interventional2003-06-30Withdrawn(stopped due to Infeasible)
Decision Support for Intraoperative Low Blood Pressure [NCT02726620]22,435 participants (Actual)Interventional2017-01-05Completed
Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure. [NCT00348504]Phase 31,300 participants Interventional2003-03-31Completed
An International Multicentre Open-label Comparative Therapeutic Exploratory Trial to Investigate the Role of a New Neonatal Formulation of Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period [NCT03311178]Phase 1/Phase 215 participants (Actual)Interventional2014-05-30Terminated(stopped due to Substudy 001B is not required at this stage of the PIP)
Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD) [NCT05210465]36 participants (Anticipated)Observational2022-03-03Recruiting
Diagnostic Impact of Low-dose Dobutamine Echocardiography in Low-flow Low-gradient Aortic Stenosis [NCT05015829]150 participants (Anticipated)Observational2019-09-01Recruiting
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock [NCT05267886]Phase 4346 participants (Anticipated)Interventional2022-03-05Recruiting
Myocardial Reserve in Advanced Heart Failure Patients [NCT05700617]Early Phase 15 participants (Anticipated)Interventional2023-07-31Not yet recruiting
Assessment of Myocardial Viability Utilizing Myocardial Contrast Echocardiography [NCT00001891]Phase 3200 participants Interventional1999-05-31Completed
Comparison of Myocardial Contrast Echo With Dobutamine Echo in Diagnosis of Coronary Artery Disease [NCT00001889]Phase 2150 participants Interventional1999-03-31Completed
Better Patient Selection to Transcatheter Aortic Valve Implantation [NCT03107923]103 participants (Actual)Observational [Patient Registry]2017-04-26Completed
The Consistency of Tracking Changes of Cardiac Output by Carotid Doppler Blood Flow and Thermodilution Technique in Cardiac Surgery Patients [NCT05944146]200 participants (Anticipated)Interventional2023-05-31Recruiting
Appropriate Timing of Complete Revascularization for Multivessel Coronary Artery Disease After Culprit Only Primary Percutaneous Coronary Intervention (PCI) for ST Elevation Myocardial Infarction [NCT02756000]120 participants (Actual)Interventional2016-01-31Completed
Comprehensive Analysis of Regional Myocardial Function in Response to Dobutamine Stress in Metabolic Syndrome and Type 2 Diabetic Patients. Effect of Cardiac Adiposity, Inflammation and Hyperglycaemia [NCT02505451]125 participants (Actual)Interventional2015-07-31Completed
Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS). [NCT03846765]Phase 436 participants (Actual)Interventional2019-07-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00763035 (7) [back to overview]Duration of Procedures
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire (Episodes of Wheezing)
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire (Episodes of Arrhythmias, Bradycardia, and Wheezing)
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire (Episodes of Arrhythmias, Bradycardia, Hypertension, and Wheezing)
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire
NCT00998205 (2) [back to overview]Change in Left Ventricle Mean Diastolic Pressure
NCT00998205 (2) [back to overview]Change in Early Transmitral Velocity/Early Lateral Mitral Velocity (E/E')
NCT02726620 (43) [back to overview]30-day Mortality
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Epinephrine
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Glycopyrrolate
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Norepinephrine
NCT02726620 (43) [back to overview]Average Use of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 50 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 55 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 60 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 65 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 70 mmHg
NCT02726620 (43) [back to overview]Depth and Duration of Intraoperative Hypotension - Threshold MAP 75 mmHg
NCT02726620 (43) [back to overview]Estimated Intraoperative Blood Loss
NCT02726620 (43) [back to overview]In-hospital Mortality
NCT02726620 (43) [back to overview]Incidence of a MAP < 50 mmHg
NCT02726620 (43) [back to overview]Incidence of a MAP < 50 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 50 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 55 mmHg
NCT02726620 (43) [back to overview]Incidence of a MAP < 55 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 55 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 60 mmHg
NCT02726620 (43) [back to overview]Incidence of a MAP < 60 mmHg for > 10 Minutes
NCT02726620 (43) [back to overview]Incidence of a MAP < 60 mmHg for > 20 Minutes
NCT02726620 (43) [back to overview]Intraoperative Administration of Intravenous Fluids
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg
NCT02726620 (43) [back to overview]Postoperative Rise in Creatinine Levels
NCT02726620 (43) [back to overview]Time to Discharge Readiness at the Postanesthesia Care Unit (PACU)
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 50 mmHg
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 55 mmHg
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 60 mmHg
NCT02726620 (43) [back to overview]Timing of Cardiovascular Drugs for MAP < 65 mmHg
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Ephedrine
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Ephinephrine
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Glycopyrrolate
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Norepinephrine
NCT02726620 (43) [back to overview]Usage Frequency of Cardiovascular Drugs: Phenylephrine
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg
NCT02726620 (43) [back to overview]Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg

Duration of Procedures

To compare the time involved during pharmacologic stress testing using regadenoson versus intravenous dobutamine in individuals with moderate to severe chronic obstructive pulmonary disease (COPD)or asthma. (NCT00763035)
Timeframe: 1 day

InterventionMinutes (Mean)
Dobutamine48
Regadenoson55

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire (Episodes of Wheezing)

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Low scores represent better outcome. (NCT00763035)
Timeframe: 1 day

Interventionnumber of episodes (Mean)
Dobutamine.2
Regadenoson0.0

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire

The Compare MD tool have the following scales: Ease of Administration - Scale from 1(most easy among all MRI stress tests) to 5(most difficult), low score represent better outcome. Patient Comfort - Scale from 1(very comfortable) to 4(very uncomfortable), low score represent better outcome. Interruptions during the procedure - Scale from 1(1-2) to 4(>6), low score represent better outcome. Side effects - Scale from 1(fewer than any other MRI stress test) to 4(the most), low score represent better outcome. Level of anxiety while during the procedure - Scale from 1(less than any other MRI stress test) to 4(the most), low score represent better outcome. Overall rating of the procedure (1 very Difficult to 5 very easy), higher scores represent better outcomes. (NCT00763035)
Timeframe: 1 day

,
Interventionunits on a scale (Mean)
Ease of administrationPatient ComfortInterruptions during the procedureSide effectsLevel of anxiety while during the procedureOverall rating of the procedure
Dobutamine2.91.80.52.32.44.3
Regadenoson1.91.50.11.61.54.1

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire (Episodes of Arrhythmias, Bradycardia, and Wheezing)

Ease of Administration of regadenoson versus intravenous dobutamine using Compare MD Questionnaire. Episodes of arrhythmias (including PVCs) and bradycardia (HR<60), low score represent better outcome. Number of Episodes of wheezing and SPO2<94%, low numbers represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionnumber of episodes (Mean)
Episodes of arrhythmias and bradycardiaEpisodes of wheezing and SPO2<94%
Dobutamine0.60.0
Regadenoson0.10.0

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Ease of Administration - Scale from 1(most easy among all MRI stress tests) to 5(most difficult), low score represent better outcome. Patient Comfort - Scale from 1(very comfortable) to 4(very uncomfortable), low score represent better outcome. Interruptions during the procedure - Scale from 1(1-2) to 4(>6), low score represent better outcome. Side effects - Scale from 1(fewer than any other MRI stress test) to 4(the most), low score represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionunits on a scale (Mean)
Ease of administrationPatient ComfortInterruptions during the procedureSide effects
Dobutamine3.42.30.62.0
Regadenoson1.51.50.11.3

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire (Episodes of Arrhythmias, Bradycardia, Hypertension, and Wheezing)

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Episodes of (SBP>140), low number represent better outcome. Episodes of arrhythmias (including PVCs) and bradycardia (HR<60), low number represent better outcome. Episodes of wheezing and SPO2<94%, low number represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionnumber of episodes (Mean)
Episodes of hypertensionEpisodes of arrhythmias and bradycardiaEpisodes of wheezing and SPO2<94%
Dobutamine1.6.80.0
Regadenoson2.80.0

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Patient Comfort - Scale from 1(very comfortable) to 4(very uncomfortable), low score represent better outcome. Interruptions during the procedure - Scale from 1(1-2) to 4(>6), low score represent better outcome. Level of monitoring - Scale from 1(most easy among all MRI tests) to 4(most difficult), low score represent better outcome. Level of anxiety while during the procedure - Scale from 1(less than any other MRI stress test) to 4(the most), low score represent better outcome. Overall rating of the procedure - Scale from 1(very difficult) to 4(very easy), higher scores represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionunits on a scale (Mean)
Patient ComfortInterruptions during the procedureLevel of monitoringLevel of anxiety while during the procedureOverall rating of the procedure
Dobutamine1.20.62.71.83.5
Regadenoson1.50.11.11.34.3

[back to top]

Change in Left Ventricle Mean Diastolic Pressure

Left ventricle filling pressures were measured using a pigtail catheter inserted into the left ventricle. Measurements of left ventricle pressures were taken at baseline, 3 minutes, 6 minutes, 9 minutes, 12 minutes, and recovery. Change from baseline at recovery reported. (NCT00998205)
Timeframe: Baseline, recovery

InterventionmmHg (Mean)
Dobutamine Stress Echo (DSE)3.3

[back to top]

Change in Early Transmitral Velocity/Early Lateral Mitral Velocity (E/E')

Echocardiography was performed at rest and with dobutamine stress at 3 minutes, 6 minutes, 9 minutes, and 12 minutes, to measure differences in E/E' at the septum and lateral mitral annulus. Change from baseline at recovery reported. (NCT00998205)
Timeframe: Baseline, recovery

InterventionRatio (Mean)
Septum E/E'Lateral E/E'
Dobutamine Stress Echo (DSE)0.4-0.4

[back to top]

30-day Mortality

Vanderbilt University Medical Center: combination of in-hospital mortality and 'alive-index' (which checks for visits to the hospital in the electronic healthcare record as indication of being alive at 30 days) (NCT02726620)
Timeframe: 30 days after surgery

InterventionParticipants (Count of Participants)
Usual Care Group511
Hypotension Decision Support143

[back to top]

Average Use of Cardiovascular Drugs: Ephedrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosages would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group20
Hypotension Decision Support15

[back to top]

Average Use of Cardiovascular Drugs: Epinephrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group1.00
Hypotension Decision Support0.70

[back to top]

Average Use of Cardiovascular Drugs: Glycopyrrolate

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group0.40
Hypotension Decision Support0.40

[back to top]

Average Use of Cardiovascular Drugs: Norepinephrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group0.62
Hypotension Decision Support0.70

[back to top]

Average Use of Cardiovascular Drugs: Phenylephrine

Cardiovascular drugs as defined under interventions. Average use for each drug will be calculated. Cardiovascular drugs that were given in <1% of cases are not reported, as the average dosage would be meaningless. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmg (Median)
Usual Care Group0.90
Hypotension Decision Support1.30

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 50 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group19
Hypotension Decision Support19

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 55 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group23
Hypotension Decision Support23

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 60 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group57
Hypotension Decision Support52

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 65 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group96
Hypotension Decision Support86

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 70 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group273
Hypotension Decision Support235

[back to top]

Depth and Duration of Intraoperative Hypotension - Threshold MAP 75 mmHg

Depth and duration of intraoperative hypotension will be modeled by calculating areas under the threshold for mean arterial pressures (MAPs). Thresholds will vary from 75 mmHg to 50 mmHg in 5 mmHg decrements. Together these variables represent the depth and duration of intraoperative hypotension. To optimize goodness of fit of these variables, the decremental steps may be increased to 10 mmHg and more restrictive lowest and highest thresholds may be chosen for the statistical analysis. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmmHg*minute (Median)
Usual Care Group485
Hypotension Decision Support417

[back to top]

Estimated Intraoperative Blood Loss

The estimated blood loss in mL during the surgical procedure (NCT02726620)
Timeframe: During the surgical procedure: an expected average of 2 hours

InterventionmL (Median)
Usual Care Group100
Hypotension Decision Support75

[back to top]

In-hospital Mortality

Hospital mortality rate during a single hospital admission after the surgery (NCT02726620)
Timeframe: All postoperative days during a single hospital admission, expected median of 5 days

InterventionParticipants (Count of Participants)
Usual Care Group487
Hypotension Decision Support137

[back to top]

Incidence of a MAP < 50 mmHg

Incidence of a mean arterial pressure (MAP) < 50 mmHg during anesthesia for 1 minute or more. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group7781
Hypotension Decision Support2196

[back to top]

Incidence of a MAP < 50 mmHg for > 10 Minutes

Incidence of a mean arterial pressure (MAP) < 50 mmHg for a cumulative duration of all hypotensive episodes of more than 10 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group1159
Hypotension Decision Support326

[back to top]

Incidence of a MAP < 50 mmHg for > 20 Minutes

Incidence of a mean arterial pressure (MAP) < 50 mmHg for a cumulative duration of all hypotensive episodes of more than 20 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group304
Hypotension Decision Support85

[back to top]

Incidence of a MAP < 55 mmHg

Incidence of a mean arterial pressure (MAP) < 55 mmHg during anesthesia for 1 minute or more. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group10991
Hypotension Decision Support3045

[back to top]

Incidence of a MAP < 55 mmHg for > 10 Minutes

Incidence of a mean arterial pressure (MAP) < 55 mmHg for a cumulative duration of all hypotensive episodes of more than 10 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group3181
Hypotension Decision Support759

[back to top]

Incidence of a MAP < 55 mmHg for > 20 Minutes

Incidence of a mean arterial pressure (MAP) < 55 mmHg for a cumulative duration of all hypotensive episodes of more than 20 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group1223
Hypotension Decision Support284

[back to top]

Incidence of a MAP < 60 mmHg

Incidence of a mean arterial pressure (MAP) < 60 mmHg during anesthesia for 1 minute or more. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group13779
Hypotension Decision Support3798

[back to top]

Incidence of a MAP < 60 mmHg for > 10 Minutes

Incidence of a mean arterial pressure (MAP) < 60 mmHg for a cumulative duration of all hypotensive episodes of more than 10 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group6989
Hypotension Decision Support1723

[back to top]

Incidence of a MAP < 60 mmHg for > 20 Minutes

Incidence of a mean arterial pressure (MAP) < 60 mmHg for a cumulative duration of all hypotensive episodes of more than 20 minutes during the anesthetic phase of the procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group3632
Hypotension Decision Support792

[back to top]

Intraoperative Administration of Intravenous Fluids

Total amount (mL) of intravenous fluids (as defined under interventions) administered during the surgical procedure. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionmL (Median)
Usual Care Group1500.00
Hypotension Decision Support1400.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg

Average concentrations of propofol infusion rates during MAP < 50 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group65.00
Hypotension Decision Support50.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg

Average concentrations of propofol infusion rates during MAP < 55 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group63.95
Hypotension Decision Support50.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg

Average concentrations of propofol infusion rates during MAP < 60 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group61.07
Hypotension Decision Support50.00

[back to top]

Intravenous Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg

Average concentrations of propofol infusion rates during MAP < 65 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionmcg/kg/min (propofol) (Median)
Usual Care Group60.10
Hypotension Decision Support48.59

[back to top]

Postoperative Rise in Creatinine Levels

Absolute values for serum creatinine before and after surgery will be compared. When multiple postoperative creatinine measurements are made, the maximum difference is reported. (NCT02726620)
Timeframe: Within 7 days after surgery

Interventionmg/dL (Median)
Usual Care Group0.00
Hypotension Decision Support0.00

[back to top]

Time to Discharge Readiness at the Postanesthesia Care Unit (PACU)

The time from arriving at the postanesthesia care unit (PACU) until the time the patient is considered ready for discharge (in minutes). (NCT02726620)
Timeframe: A specific time frame on the day of surgery: from the start of admission to the PACU to discharge from the PACU, an expected average of 4 hours

Interventionminutes (Median)
Usual Care Group67
Hypotension Decision Support60

[back to top]

Timing of Cardiovascular Drugs for MAP < 50 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 50 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group1
Hypotension Decision Support0

[back to top]

Timing of Cardiovascular Drugs for MAP < 55 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 55 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group1
Hypotension Decision Support0.5

[back to top]

Timing of Cardiovascular Drugs for MAP < 60 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 60 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group0.8
Hypotension Decision Support1.5

[back to top]

Timing of Cardiovascular Drugs for MAP < 65 mmHg

Cardiovascular drugs as defined under interventions. Time of first administration of cardiovascular drug relative to the time at which the mean arterial pressure (MAP) drops below 60 mmHg. Per patient the average time to first administration of all hypotensive episodes was calculated. That average time is used as the outcome variable. A negative value indicates that administration occurred before the drop in MAP. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

Interventionminutes (Median)
Usual Care Group2
Hypotension Decision Support1.14

[back to top]

Usage Frequency of Cardiovascular Drugs: Ephedrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group9310
Hypotension Decision Support2718

[back to top]

Usage Frequency of Cardiovascular Drugs: Ephinephrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group1215
Hypotension Decision Support409

[back to top]

Usage Frequency of Cardiovascular Drugs: Glycopyrrolate

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group11093
Hypotension Decision Support1257

[back to top]

Usage Frequency of Cardiovascular Drugs: Norepinephrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group762
Hypotension Decision Support233

[back to top]

Usage Frequency of Cardiovascular Drugs: Phenylephrine

Cardiovascular drugs as defined under interventions. Frequency of patients receiving the drug. Cardiovascular drugs that were given in <1% of cases are not reported. (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

InterventionParticipants (Count of Participants)
Usual Care Group12211
Hypotension Decision Support3685

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 50 mmHg

Average concentrations of inhalational anesthesia during MAP < 50 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.230.654.70
Usual Care Group1.320.654.28

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 55 mmHg

Average concentrations of inhalational anesthesia during MAP < 55 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.250.674.65
Usual Care Group1.340.684.60

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 60 mmHg

Average concentrations of inhalational anesthesia during MAP < 60 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.250.672.33
Usual Care Group1.350.684.36

[back to top]

Inhaled Anesthetic Drug Use During Intraoperative Hypotension: MAP < 65 mmHg

Average concentrations of inhalational anesthesia during MAP < 65 mmHg episodes (NCT02726620)
Timeframe: During the anesthetic phase of the surgical procedure: an expected average of 2.5 hours

,
InterventionEndTidal% (other) (Median)
Sevoflurane (EndTidal %)Isoflurane (EndTidal %)Desflurane (EndTidal %)
Hypotension Decision Support1.270.682.31
Usual Care Group1.350.684.10

[back to top]